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Antibiotic resistance in Mycobacterium tuberculosis is a worldwide problem as it drastically affects 
patient treatment outcome. The development of drug resistance is due to the acquisition of 
mutations in drug resistance conferring genes. Early detection of drug resistance is vital to improve 
patient therapy and prevent the transmission of drug resistant strains. It is therefore important to 
develop a method that is able to accurately detect minority variants conferring drug resistance to 
prevent treatment failure. The aim of this study was to develop an ultrasensitive method to detect 
underlying resistance causing variants in specific M. tuberculosis fluoroquinolone resistance 
causing genes (gyrA and gyrB).  
Efficient primer sets were used to amplify the quinolone resistance-determining region of gyrA and 
gyrB. Targeted deep sequencing was done using the Ion Torrent Personal Genome Machine 
(PGM) and Illumina MiSeq platforms and sequencing data were analysed using the appropriate 
bioinformatics tools for the respective platforms. The method was validated using synthetic 
heterogeneous mixtures and was subsequently applied to identify underlying variants in patient 
isolates showing the acquisition of fluoroquinolone resistance.  
The Illumina MiSeq platform was shown to be superior to the Ion Torrent PGM platform as it 
accurately detected the correct proportion of mutant DNA to a minimum frequency of 0.1%. We 
also showed that targeted deep sequencing is sensitive and able to detect underlying variants 
emerging and fluctuating during the evolution of fluoroquinolone resistance. These results show 
great promise for the development of an ultrasensitive diagnostic method for the early detection of 











Antibiotikum weerstandigheid in Mycobacterium tuberculosis is ‘n wêreld-wye probleem omdat dit 
die uitkoms van die behandeling van tuberkulose pasiënte drasties beinvloed. Die ontwikkeling van 
middelweerstandigheid is as gevolg van die verkryging van mutasies in middelweerstandige 
veroorsakende gene. Die vroeë identifisering van middelweerstandigheid is belangrik om die 
behandeling van pasiënte te bevorder, asook om die transmissie van middelweerstandige stamme 
te verhoed. Dit is dus belangrik om ‘n metode te ontwikkel wat akkuraat is in die identifisering van 
onderliggende mutasies wat middelweerstandigheid veroorsaak. Die doel van hierdie studie was 
om ‘n uiters sensitiewe metode te ontwikkel vir die identifisering van onderliggende mutasies in die 
fluoroquinolone weerstandigheids gene (gyrA en gyrB). 
Effektiewe inleiers was gebruik om die quinolone weerstandigheids-bepalende area van gyrA en 
gyrB te amplifiseer. Geteikende diep deoksiribonukleïensuur (DNS) volgorde bepaling was gedoen 
deur gebruik te maak van die Ion Torrent Personal Genome Machine (PGM) en die Illumina MiSeq 
platform. Die volgorde bepaling data was geanaliseer deur toepaslike bioinformatika sagteware vir 
die onderskeie platforms. Die metode was getoets deur gebruik te maak van sintetiese 
heterogeniese DNS mengsels en was verder toegepas om onderliggende mutasies in pasiënt 
isolate wat die verkryging van fluoroquinolone weerstandigheid wys, te identifiseer. 
Die Illumina MiSeq platform was beter as die Ion Torrent PGM platform, siende dat dit met 
akkuraatheid die korrekte verhouding van mutant DNS by ‘n minimum frekwensie van 0.1% kon 
wys. Die studie het ook gevind dat geteikende diep DNS volgorde bepaling sensitief en instaat is 
om onderliggende mutasies te identifiseer wat ontluik en wisselend voorkom tydens die evolusie 
van fluoroquinolone weerstandigheid. Hierdie resultate is belowend vir die ontwikkeling van ‘n 
uiters sensitiewe diagnostiese metode vir die vroeë opsporing van fluoroquinolone 
weerstandigheid wat teneinde die tuberkulose beheerprogram kan verbeter. 
 
  




With men this is impossible, but with God all things are possible. 
 Matthew 19:26 
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Chapter 1: General introduction 
Background and motivation of the study 
Tuberculosis (TB) control programmes world-wide are faced with the challenge that 
Mycobacterium tuberculosis isolates have evolved to become resistant to the available anti-
TB drugs. Of major concern is M. tuberculosis that has become resistant to the best 
available drugs isoniazid and rifampicin, which are defined as multi-drug resistant 
tuberculosis (MDR-TB). According to the World Health Organization (WHO), MDR-TB is a 
global problem and an estimated 480 000 people developed MDR-TB in 2015 (WHO, 
2015a). Recent MDR-TB prospective cohort studies have demonstrated that approximately 9 
to 15% of MDR-TB patients develop resistance to fluoroquinolones (FQs) while on treatment 
(Cegielski et al., 2014). FQ resistance have been associated with increased mortality 
(between 50-80%), high risk of progression to XDR-TB (MDR-TB with additional resistance 
to a second-line injectable as well as a FQ) and the potential spread of preXDR-TB (MDR-
TB with additional resistance to either a second-line injectable or a FQ) (Pantel et al., 2012). 
FQs are widely used antibiotics with a broad-spectrum antimicrobial activity (Wang et al., 
2007). FQs target the enzyme, DNA gyrase, which consist of two alpha and two beta 
subunits encoded by gyrA and gyrB, respectively (Miotto P.; Cirillo D.M.; Migliori B., 
2015).The function of DNA gyrase is to relieve stress while double-stranded DNA is being 
unwound by helicase into single stranded DNA which then allows for the initiation of DNA 
replication by DNA polymerase (Miotto P.; Cirillo D.M.; Migliori B., 2015). The loss of the 
DNA gyrase function will result in cell death (Miotto P.; Cirillo D.M.; Migliori B.; 2015). 
Variants in gyrA cause the FQ resistance and reduces negative supercoiling which results in 
large-scale changes to gene expression, altering broad antimicrobial susceptibility as well as 
fitness and evolutionary adaptability. Amino acid substitutions within a short conserved 
region within gyrA (codon 74 – 113) and gyrB (codon 500 – 538) are referred to as the 
quinolone resistance-determining region (QRDR) (Wang et al., 2007). Mutations within the 
QRDR regions affect the binding of the antibiotic to the gene protein. Importantly, the 
majority of known FQ-resistant M. tuberculosis strains are associated with mutations in the 
QRDR of gyrA (Al-Mutairi et al., 2011). To date resistance to FQs has been determined by 
phenotypic culture based methods. However, these methods are slow and require complex 
infrastructure to ensure biosafety. In 2016 the WHO endorsed the use of the GenoType 
MTBDRsl line probe assay which detects mutations in the gyrA and gyrB gene of M. 
tuberculosis. This method of FQ drug susceptibility testing is envisaged to shorten the 
turnaround time from 50 days (culture) to <5 days. However the implementation of genetic 




drug susceptibility testing has certain limitations which need to be considered when making 
a diagnosis. Firstly the GenoType MTBDRsl assay does not detect all of the mutations 
conferring FQ resistance and secondly the assay is only able to detect subpopulations of FQ 
resistant M. tuberculosis if they are present at >5% (as compared to >1% for culture-based 
methods) (Folkvardsen, Thomsen, et al., 2013).  
We know that FQ resistance in M. tuberculosis develops spontaneously through mutation in 
the gyrA and gyrB genes (Mayer & Takiff, 2014) and during treatment with an FQ the 
resistant subpopulation will be selected. The proportion of resistant clones within an 
individual will be exceptionally low at the point when resistance develops and with time will 
increase in the presence of FQ to a proportion that is  by culture (>1%) and finally until 100% 
of the population is FQ resistant. Thus the low sensitivity of genetic drug susceptibility tests 
for detecting underlying propulations may be explained by their inability to detect gyrA or 
gyrB mutations in some clinical isolates of M. tuberculosis which are below 5%.(Chakravorty 
et al., 2011). 
Previous studies have shown the existence of both gyrA wildtype and gyrA mutant 
populations in the same M. tuberculosis clinical isolate (van Rie et al., 2005; Streicher, 
Bergval, et al., 2012). The presence of both resistant and susceptible population has been 
termed heteroresistance. In addition, the above studies also showed that multiple gyrA 
mutations could be present in the same M. tuberculosis isolate, and that the frequency of 
these mutations can vary over time (van Rie et al., 2005; Streicher, Bergval, et al., 2012). 
The presence of multiple heterogeneous genotypes in an isolate adds to the complexity for 
the identification of drug resistance as current molecular techniques fail to detect underlying 
populations below the 5% threshold. Furthermore this study showed that the discordance 
between genotype and phenotype could be resolved by initially culturing the isolate on FQ 
containing media and then sequencing the individual colonies. In all instances classical gyrA 
mutations were identified thereby reconfirming the association between gyrA mutations and 
FQ resistance and questioning the role of other gene mutations in FQ resistance.  
The sensitivity of currently available genetic drug susceptibility tests to detect underlying 
resistant subpopulations is greater than 5% for the line probe assays (Engström et al., 2013; 
Folkvardsen, Thomsen, et al., 2013). Sanger sequencing is of the order of 10% 
(Folkvardsen, Svensson, et al., 2013), while Xpert MTB/RIF can accurately detect underlying 
resistance if the proportion of resistant clone is >60% (Engström et al., 2013; Folkvardsen, 
Thomsen, et al., 2013). Ideally, molecular methods should be able to accurately detect the 
presence of ≤1% underlying populations in order to identify the emergence of resistant 
clones during treatment. 




We propose to use targeted deep sequencing to identify minority clones harboring FQ 
resistance conferring mutations in serial patient isolates initiated on MDR-TB treatment. This 
will allow us to determine whether the resistant clones that emerged on therapy were initially 
present prior to the start of treatment or were emerged due to antibiotic pressure. 
Hypotheses 
In this study we hypothesize that targeted deep sequencing can be used to identify 
underlying drug resistance variants in M. tuberculosis clinical isolates.  
Aims  
To develop an ultrasensitive method to detect resistance-causing variants (mutations) 
directly from sputum using targeted deep sequencing. 
To use targeted deep sequencing to detect underlying mutant variants in synthetically 
created heterogeneous mixtures. 
To use targeted deep sequencing to detect underlying mutant variants in FQ-susceptible 
clinical isolates. 
To use targeted deep sequencing on clinical samples to determine whether underlying 
resistant clones were initially present, and subsequently selected for under antibiotic 
pressure or whether drug resistant clones emerge during treatment as a result of a mutation. 
Objectives 
Therefore, the objectives of this study were to use targeted deep sequencing to: 
1. Amplify the quinolone resistance determining region (QRDR) of gyrA and gyrB genes 
of M. tuberculosis. 
2. Create and amplify in vitro artificial heterogeneous mixtures (WT:MU) to determine if 
the targeted deep sequencing method is able to detect approximately known 
underlying variants (<10%) (e.g. SNP) within the QRDR region of gyrA and gyrB 
genes of M. tuberculosis. 
3. Determine the sensitivity of the method by amplification of diluted artificially created 
heterogeneous mixtures and Sanger sequencing there off. 
4. Use clinical isolates to determine M. tuberculosis population dynamics, i.e. whether 
the minority population is present and to observe/see whether it becomes dominant 
and fixed over time (i.e. during treatment period). 
5. Optimize a deep sequencing method to detect a 1% minority variant population of M. 
tuberculosis in clinical specimens. 




6. Determine whether FQ resistant M. tuberculosis clones that emerge in MDR-TB 
patients while on therapy were initially present (minority variants) and were simply 
selected for under antibiotic pressure or whether they developed as a result of de 
novo mutations.  




Chapter 2: Literature review: Heteroresistance in 




Tuberculosis (TB) infected 9.6 million people globally and caused 1.5 million deaths in 2014 
(World Health Organization, 2016). This highly infectious disease is caused by 
Mycobacterium tuberculosis a bacterium that is able to develop drug resistance to the 
available antibiotics that constitute the five drug anti-TB regimen. Drug resistance to multiple 
drugs in the first-line anti-TB drug regimen, including at least rifampicin (RIF) and isoniazid 
(INH), has been termed multi-drug resistant tuberculosis (MDR-TB) (WHO, 2015b). MDR-TB 
is a global concern as an estimated 480,000 cases of MDR-TB are detected each year 
(WHO, 2015b). Furthermore, current second-line anti-TB treatment is toxic, poor treatment 
outcomes are common and inappropriate or interrupted treatment may promote amplification 
of resistance (Cegielski et al., 2014).  
Successful treatment of MDR-TB cases is dependent on prior knowledge of the infecting 
strain’s drug susceptibility pattern. Guidelines for drug susceptibility testing (DST) as well as 
critical concentrations for first and second-line drugs have been formulated by the World 
Health Organization (WHO) (WHO, 2008a). These guidelines recommend the proportion 
method for the identification of subpopulations of drug-susceptible and drug resistant bacilli 
(Folkvardsen, Svensson, et al., 2013). Using the current guidelines, a drug resistant 
subpopulation consisting of ≥1% of the total population can be detected when M. 
tuberculosis is exposed to fixed concentrations of antimicrobials (e.g. INH, RIF, ethambutol 
(EMB), and streptomycin (SM)) (Engström et al., 2013). This method is highly sensitive and 
remains the gold standard for phenotypic DST, despite, has an average four week 
turnaround time. Alternatively, molecular diagnostic methods (e.g. Xpert MTB/RIF (Cepheid, 
Sunnyvale, USA) and Genotype MTBDRplus (Hain Lifescience, Nehren, Germany)) have 
been endorsed by the WHO to identify genomic variations conferring drug resistance in 
clinical M. tuberculosis isolates (World Health Organization, 2007; Schurch, Kremer, 
Daviena, et al., 2010; Schurch, Kremer, Kiers, et al., 2010). The Xpert MTB/RIF assay can 
detect mutations in the rifampicin resistance determining region (RRDR) of rpoB, while the 
Genotype MTBDRplus assay can be used as a diagnostic and confirmatory test for MDR-TB 
as it can also identify mutations in katG and the promoter region of inhA promoter (Rahman 




et al., 2016). WHO-approved molecular diagnostic methods are notably less sensitive than 
culture-based methods to detect subpopulations of resistant bacilli (Blakemore et al., 2010). 
The current molecular methods are able to detect drug resistant subpopulations that 
represent ≥10% of the total population, however, the detection ability varies greatly between 
molecular methods (Engström et al., 2013; Folkvardsen, Svensson, et al., 2013; 
Folkvardsen, Thomsen, et al., 2013).  
This variability implies that genetic DSTs may fail to identify subpopulations of resistant 
bacilli, which may in part explain the observed discordance between phenotype and 
genotype in a limited proportion of cases (Streicher, Muller, et al., 2012; Folkvardsen, 
Svensson, et al., 2013; Folkvardsen, Thomsen, et al., 2013) where genetic DST classifies 
the M. tuberculosis strain as susceptible, whilst phenotypic DST classifies the strain as 
resistant. Failure to identify the resistant subpopulations leads to antibiotic selection of this 
subpopulation with concomitant treatment failure (van Rie et al., 2005). Another limitation of 
genetic DST is that it does not detect the full repertoire of mutations conferring resistance 
and thus specimens harbouring rare mutations conferring resistance will not be detected 
(Campbell et al., 2011). For this reason genetic DST is a “rule in” test and a secondary test 
may be required if genetic resistance is not detected (Wedajo et al., 2014). This limits the 
usefulness of genetic tests for detecting the emergence of resistance during treatment and 
explains why culture based methods remain the gold standard for DST. 
Adding to the complexity of M. tuberculosis drug resistance and diagnosis thereof is intra-
patient co-existence of clonal subpopulations displaying different drug resistance allele 
combinations, despite having the same IS6110 fingerprint, otherwise known as 
heteroresistance (Merker et al., 2013). Possible causes of heteroresistance are (I) in host 
evolution of a single strain as a result of acquisition of drug resistance during treatment (Sun 
et al., 2012), or (II) infection with more than one strain (mixed infection) as a result of 
transmission (van Rie et al., 2005; Wang et al., 2015). Currently, the prevalence of 
heteroresistance in M. tuberculosis is unknown due to a paucity of studies in this area 
(Folkvardsen, Thomsen, et al., 2013). A possible reason is the lack of a standard definition 
of heteroresistance, which may result in misidentification of heterogeneous strains as 
heteroresistance, and may hinder proper assessment of the clinical significance of 
heteroresistance (El-Halfawy & Valvano, 2015). For example, heteroresistance in M. 
tuberculosis was defined as the presence of both susceptible and resistant strains in 
different proportions in the same patient (Hofmann-Thiel et al., 2009; Folkvardsen, Thomsen, 
et al., 2013). Subsequently, it was redefined as the coexistence of populations with different 
variants (nucleotides) at a drug resistance conferring locus within a sample of organisms 
(Eilertson et al., 2014). For the purpose of this review, we consider heteroresistance to be 




the coexistence of drug-resistant and -susceptible bacteria in the same patient sample. This 
is in accordance with Hofmann-Thiel et al. (2009), Folkvardsen et al. (2013), and Thomsen, 
et al. (2013). 
In this review, we assess the published literature on heteroresistance in M. tuberculosis and 
compare the sensitivities of current diagnostic methods to detect heteroresistance in M. 
tuberculosis. We also critically review the published literature on next generation sequencing 
(NGS) technology, specifically targeted deep sequencing, as a potential genetic test to 
diagnose low-frequency drug resistant subpopulations of ≤1%. Furthermore, we discuss the 
clinical relevance of heteroresistance and of NGS technology as a diagnostic tool to detect 
heteroresistance, as well as provide suggestions for future studies on heteroresistance.   





The prevalence of heteroresistance in M. tuberculosis is currently unknown. However, 
studies have identified heteroresistance in M. tuberculosis against numerous anti-TB drugs, 
showing that heteroresistance is not restricted to a particular resistance associated gene 
(Rinder et al., 2001; Zhang et al., 2012). For example, heteroresistance has been 
documented in rpoB for RIF (Hofmann-Thiel et al., 2009), in katG and oxyR-ahpC for INH 
(Zhang, Lu, et al., 2014), in quinolone resistant determining (QRDR) regions of both gyrB 
and gyrA genes for fluoroquinolone (FQ) (Streicher, Bergval, et al., 2012; Eilertson et al., 
2014).  
Furthermore, heteroresistance contributes to M. tuberculosis fitness, since, it allows for 
alteration of strain dominance according to the type of external threats that M. tuberculosis 
strains are exposed to (Streicher, Bergval, et al., 2012). Black et al. (2015) observed similar 
results with the emergence and disappearance of variants during the evolution of drug 
resistance, as a result of anti-TB drugs exerting a selective pressure on the M. tuberculosis 
strains under study (Black et al., 2015). The fluctuating variants resulted in a purifying effect 
through the loss of heterogeneous variants (Black et al., 2015). This is in agreement with an 
earlier study that also observed strain dominance being influenced by treatment and 
adherence (van Rie et al., 2005). Alternatively, treatment with less-effective second-line 
drugs led to re-emergence of a drug-susceptible strain in a patient with mixed infection, 
demonstrating that strain dominance in sputum culture is determined by the selection 
pressure of the antibiotic therapy (van Rie et al., 2005). This in turn allows the existence, 
persistence and spread of TB disease with various degrees of drug resistance, which affect 
diagnosis (Meacci et al., 2005).  
Diagnosis of heteroresistance in M. tuberculosis depends on various factors. Primarily, the 
source of isolates, since different sources (i.e. original clinical sputum specimen (genolyse 
samples) vs cultured isolate) may result in different ratios of the wild type and mutant strains 
within the M. tuberculosis population (Rinder et al., 2001; Mekonnen et al., 2015). In 
particular, culturing in the presence or absence of a drug, may alter the ratio of drug 
sensitive and drug resistant populations, depending on the fitness cost of the drug resistance 
conferring mutation (van Rie et al., 2005; Zetola et al., 2014). Furthermore, decontamination 
methods also influence the detection of the true presence of heteroresistance within a 
sample as a large proportion of mycobacteria is inadvertently killed by the process 
(Chatterjee et al., 2013). For example, 4% NaOH, a strong decontaminant, has been 
observed to kill 60% of tubercle bacilli present in the specimen (Chatterjee et al., 2013). As a 
result, the true composition of resistant and susceptible populations present within the 
decontaminated specimens may be altered and in some cases result in heteroresistance 




being overlooked (Chatterjee et al., 2013). Furthermore, different growth media result in 
variation in growth rates, for example faster growth is observed in liquid media compared to 
Löwenstein-Jensen solid medium and solid Middlebrook 7H11 agar, which would in turn 
affect phenotypic resistance tests and molecular assays (Rinder et al., 2001). It has also 
been shown that some drug resistance causing mutations are associated with a fitness cost 
in the absence of the antibiotic (van Rie et al., 2005) and therefore it is possible that the fitter 
strain (i.e. susceptible or resistant strain, depending on whether the antibiotic is present or 
not) will outgrow the weaker strain and as a result alter the true ratio of wild type and mutant 
strains. The above mentioned factors question the reliability of culture as an accurate 
reflection of the composition of the true variants in a clinical sample (El-Halfawy & Valvano, 
2015). Lastly, the sensitivity of the diagnostic method used will determine whether the low-
frequency resistance-causing variants in M. tuberculosis will be detected or not, see (Figure 
1) (Mekonnen et al., 2015). 
Current diagnostic methods apply conventional culture-based phenotypic DST on solid or 
liquid culture media, which is highly sensitive for detecting drug-resistant TB (Folkvardsen, 
Thomsen, et al., 2013; Hughes et al., 2014). This gold standard phenotypic test is able to 
classify an M. tuberculosis population as resistant or susceptible and to detect underlying 
resistant bacilli if at least 1% of the bacterial population is resistant (Engström et al., 2013; 
Zhang, Lu, et al., 2014). Furthermore, studies have found that solid culture (i.e. the broth 
dilution method) has a greater sensitivity in detecting heteroresistance (e.g. INH and RIF) 
compared to liquid culture (i.e. Mycobacteria Growth Indicator Tube (MGIT) DST) (Zhang, 
Lu, et al., 2014; Zhang, Wang, et al., 2014). In particular, the broth dilution method is able to 
detect INH resistance if 0.5% of resistant bacteria are present, typically harbouring mutations 
in katG and/or oxyR-ahpC genes (according to the study’s observation), compared to the 
MGIT system that is able to detect 1% INH resistant M. tuberculosis bacteria (Zhang, Lu, et 
al., 2014). Furthermore, the broth dilution method is able to detect INH heteroresistance in 
M. tuberculosis isolates with mutations in the promoter region of the inhA gene as opposed 
to liquid culture that cannot, owing to low-level INH resistance (Zhang, Lu, et al., 2014). 
Conversely, the detection ability of MGIT DST for RIF resistance depends on the type of M. 
tuberculosis lineage, for example, MGIT DST that was done in the same laboratory was able 
to detect 1% RIF resistance for Haarlem strains, as opposed to identifying 5% RIF 
resistance for the Beijing strains (Folkvardsen, Thomsen, et al., 2013). It was however 
speculated that the different rpoB muations found in the particular Beijing and Haarlem 
strains are associated with different fitness costs which may affect the ability of DST 
methods to detect heteroresistance. Notably, there is a lack of information on the ability to 




detect heteroresistance for the other anti-TB antibiotics when using either solid or liquid 
media DST methods. 
Alternatively, heteroresistance can be detected from sputum or cultured samples by making 
use of traditional polymerase chain reaction (PCR) and gel electrophoresis, followed by 
restriction fragment length polymorphism analysis of polymerase chain reaction products 
(PCR-RFLP) (Rinder et al., 2001). The extensive use of PCR and gel electrophoresis as 
diagnostic techniques in the laboratory has led to advances in PCR based detection 
technology to improve its diagnostic ability. For example real-time PCR and digital PCR has 
enabled quantification and improved detection of heteroresistance in M. tuberculosis to a 
level of 10% and 0.1%, respectively, indicating that PCR-based technologies also vary 
greatly in their sensitivity to detect heteroresistance (Pholwat et al., 2013). Furthermore, the 
addition of sloppy molecular beacons (SMBs) to real-time PCR methods allows for rapid 
detection of FQ resistance and emergence of as little as 5% FQ heteroresistance in clinical 
samples from TB patients (Chakravorty et al., 2011). However, concern over consistency of 
different PCR runs with the same clinical genotypes has been raised, following the outcome 
of a study that showed different genotypes from reruns of the same sample (Rinder et al., 
2001). The authors suggest that the inconsistency could be due to stochastic events 
occurring during the initial PCR cycles (Rinder et al., 2001). A possible solution to this 
problem is to repeat the PCR step a number of times, however this is very time and resource 
consuming. 
An alternative applied diagnostic, namely Sanger sequencing, is an automated method of 
DNA sequencing built upon the chemistry of PCR. The method results in the termination of 
the extending DNA fragment, by the addition of fluorescently labelled dideoxy chain-
terminating nucleotides by DNA polymerase during in vitro DNA replication. Sanger 
sequencing is used for analysing sequence variants as well as for detecting resistance-
causing mutations (Sanger & Coulson 1975, Sanger, Nicklen & Coulson 1992). This 
genotypic test is also able to detect low frequency variants (heteroresistance) at a sub-
population of ≥10% (Folkvardsen, Svensson, et al., 2013). A different DNA sequencing 
method, namely Pyrosequencing, relies on the detection of pyrophosphate release, detected 
as emitted light, on nucleotide incorporation (Engström et al., 2013). This method is not as 
sensitive as Sanger sequencing, but has the ability to detect 35-50% low-frequency 
resistance-associated mutations in M. tuberculosis (Engström et al., 2013). 
In 2008, the WHO endorsed the line-probe assay (LPA) GenoType MTBDRplus VER1.0 
(Hain Lifescience, Nehren, Germany) for rapid diagnosis of MDR-TB (WHO, 2008b; Hughes 
et al., 2014). This PCR-based genotypic test amplifies genes where mutations associated 




with resistance are common (for example mutations in the rpoB gene that result in RIF 
resistance) and then hybridizes the target sequences to a membrane strip (Folkvardsen, 
Svensson, et al., 2013). Resistance is then represented by the presence of specific mutation 
bands or the absence of wild type bands on the visualised strip (Folkvardsen, Svensson, et 
al., 2013). Drug resistance to the first line drugs RIF and INH can be detected directly from 
smear-positive sputum specimens with the GenoType MTBDRplus (Hughes et al., 2014). 
Furthermore, the GenoType MTBDRplus is also able to detect heteroresistance when the 
relative proportion of resistant M. tuberculosis organisms is ≥5% and harbour the specified 
known resistance causing mutations (Hofmann-Thiel et al., 2009; Folkvardsen, Svensson, et 
al., 2013; Folkvardsen, Thomsen, et al., 2013). Folkvarsen et al. (2013) has also showed 
that the GenoType MTBDRplus is superior to INNO-LiPA in detecting heteroresistance 
(Folkvardsen, Thomsen, et al., 2013). 
Subsequently, in 2010, the WHO endorsed the Xpert MTB/RIF (Cepheid, Sunnyvale, USA) 
for TB diagnosis (WHO, 2011), and it has subsequently become the routine first-line 
diagnostic test in South Africa (Hughes et al., 2014). This assay is highly regarded for its 
high specificity and fast turnaround time (Mayer & Takiff, 2014). However, the Xpert 
MTB/RIF assay is only able to detect RIF resistance-conferring mutations only if the rpoB 
mutation is present in ≥65% of the bacterial population. A possible reason is the principle of 
the Xpert test that only detects resistance when the signal of the molecular beacon probes is 
either lost or reduced, attributable to mutations in the rpoB gene that inhibit hybridization of 
one or more molecular beacons specific to rpoB gene. An alternative reason is the particular 
rpoB mutation that could influence the level at which heterogeneity can be detected, since 
common RIF resistance causing mutations result in the complete inhibition of probe 
hybridization whereas uncommon rpoB mutations only results in partial probe hybridization 
(Blakemore et al., 2010). Studies have also observed high false-positive RIF resistance 
results within strains with a wild type rpoB gene sequence (Boehme et al., 2011; Marlowe et 
al., 2011; Theron et al., 2011; van Rie et al., 2013).  
Recently, an increasing number of studies have reported using highly improved genomic 
diagnostic techniques such as whole genome sequencing (WGS) and targeted deep 
sequencing to identify resistance causing variants, establish relapse or re-infection, reveal 
genomic heterogeneity within M. tuberculosis, to name a few (Bryant et al., 2013; Black et 
al., 2015; Colman et al., 2016). These techniques provide a detailed view of the genomic 
structure of the pathogen, including alterations (for example single nucleotide 
polymorphisms (SNPs), short insertions and deletions (in/dels) and regions of difference 
(RDs)) in the genome which may assist with TB drug resistance diagnostics. Alternatively, 
these techniques can be used for epidemiological studies, phylogenetic studies, population 




studies and research in drug development of anti-TB drugs (Gardy et al., 2011; Ioerger et al., 
2013; Walker et al., 2013).  
Recent studies have investigated the ability of WGS to identify genetic heterogeneity (Black 
et al. (2015) and showed that a read frequency cut-off of 30% is adequate to identify low 
frequency sequencing variants in M. tuberculosis with high confidence, at an ever 
decreasing cost and increasing throughput (Black et al., 2015). However, WGS currently 
cannot be used as a routine clinical diagnostic tool due to cost and computational 
intensiveness, but despite these limitations, it remains a useful discovery tool in academic 
settings.  
Advancement in NGS technology and computational capacity, more specifically next 
generation targeted deep sequencing, has made it possible to detect drug resistance 
causing genetic variants present at a low frequency (≥0.1%) prior to or during treatment of 
M. tuberculosis infected patients (Colman et al., 2015). The extremely high sensitivity, allows 
targeted deep sequencing to out-perform all of the previous genomic diagnostic assays, 
making it the most sensitive and specific genomic assay presently available. 
Targeted deep sequencing refers to sequencing of a defined genomic region multiple times, 
where sequence depth (depth of coverage) refers to the number of times a given region is 
covered by individual reads (“Illumina”, 2016). Targeted deep sequencing is a powerful tool 
to investigate evolving bacterial as well as viral populations, provided that variants are 
accurately identified during data analysis. Targeted deep sequencing can also be useful for 
drug resistance diagnostics, as it can be applied to detect an extremely low-level (≥0.1%) of 
resistance conferring genetic variants at a minimum depth of 10 000x coverage (Colman et 
al., 2015). The latter study showed that the limit of detection of heterogeneity using targeted 
deep sequencing is inversely proportional to the total depth of coverage (Colman et al., 
2015). However, the clinical relevance of ≥0.1% subpopulation detection is yet to be 
confirmed (Colman et al., 2015).  
In the study by Colman et al. (2015), rare M. tuberculosis drug resistant subpopulations were 
detected using targeted deep sequencing (with an Illumina sequencing platform) together 
with single molecule-overlapping reads (SMOR) analysis. Initially, the method (SMOR) was 
validated using standardized mixtures of DNA from susceptible and resistant M. tuberculosis 
isolates followed with DNA directly extracted from clinical sputum samples (Colman et al., 
2015). The SMOR analysis allows for tracking and quantification of low frequency 
subpopulations by using sequence information from overlapping paired-end reads (forward 
and reverse). A minimum of 2000x depth of coverage (1000x paired reads) is required for 
the detection of a 1% subpopulation, which is equal to 10 pairs of reads (Colman et al., 




2015). In the study, the same DNA molecule was used for the quantification and detection of 
drug resistance conferring SNPs in six different target gene regions (rpoB, inh promoter, 
katG, gyrA, rrs and eis promoter) in artificially mixed subpopulations (Colman et al., 2015). 
These mixed subpopulations consisted of an extensively drug resistant- (XDR) (ranging from 
0.025% to 70% of the mixture) and a pan-susceptible M. tuberculosis strain (Colman et al., 
2015). The results showed that targeted deep sequencing with SMOR analysis had a greater 
sensitivity than standard molecular approaches (Sanger sequencing, NGS analysis and 
other WHO endorsed molecular methods) (Colman et al., 2015). In addition, SMOR analysis 
allows for in silico examination of the genetic changes occurring over time in mixed 
subpopulations of M. tuberculosis, which allows rapid characterization and evaluation for 
clinical significance (Colman et al., 2015). However, this study used the SMOR analysis by 
only calling variants at specific positions in the target gene regions. This approach may 
prevent the discovery of novel drug resistance causing mutations and mask the presence of 
low frequency (0.1-0.4%) false positive variants across the entire targeted area as the error 
rate of Illumina is around 0.4% (Quail et al., 2012). 
Other NGS platforms have also been utilized for targeted deep sequencing, namely the Ion 
Torrent Personal Genome Machine (PGM) and Ion Proton, the Pacific Bioscience RS and 
Illumina MiSeq sequencers, however each has its own strengths and limitations, which have 
been discussed elsewhere in a comparative study of NGS platforms (Quail et al., 2012). The 
latter study included both Prokaryotic (haploid) and eukaryotic (diploid) organisms which 
represented a range of genotypic features such as GC-rich regions, AT-rich regions and 
repetitive regions (Quail et al., 2012). The maximum sequencing yield (referring to the 
number of reads per run) of each platform ranges from  .5- .5   10
 
 for the PacBio RS II: 
P6-C4 platform, to  .2  10
 
 for Ion Torrent (PGM), and     10
 
 (paired) for Illumina HiSeq 
2500 (Rhoads & Au, 2015). The sequences generated from these platforms differ in quality 
which can be used to inform the analysis of the data for certain diagnostic applications. 
Therefore it is important to consider the following before implementing targeted deep 
sequencing: (I) the type of platform, (II) research question (hypothesis), (III) available 
resources, (IV) sequencing and data analysis expertise, (V) finances, (VI) infrastructure, (VII) 
repeat elements, (VIII) GC-rich -, and (IX) AT-rich content of the organism under study (Quail 
et al., 2012). The type of sequencing platform may determine the diagnostic applications and 
the limit of detection. 
Furthermore, the research question determines the type of platform required for sequencing, 
software needed to analyse the data and the minimum depth of coverage required, which is 
also influenced by the available expertise, as currently available data analysis software is 




largely specialised. The GC content of the organism can also influence the outcome and 
performance of the various NGS platforms (Roetzer et al., 2013). Furthermore, the depth of 
coverage, read length, and error rate of NGS platforms also contribute to the confidence, 
accuracy and validity of the variants called by a particular variant caller (analysis tool kit).  
The major advantage of targeted deep sequencing, as seen above, is that it has the 
potential to detect low frequency genetic variants in heterogeneous populations. Other 
advantages of targeted deep sequencing are fast turnaround (large numbers of samples in a 
single run and target multiplexing), the ability to sequence low levels of degraded DNA, and 
the ability to provide realistic reconstruction of individual bacterial haplotypes because of an 
increase in read length (McElroy et al., 2014). 





Figure 1 Diagnostic sensitivity of current diagnostic assays to detect underlying drug resistance. DST=drug susceptibility test. 
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Clinical relevance of heteroresistance in M. tuberculosis 
The current literature reflects ambiguity surrounding heteroresistance, possibly driven by the lack 
of a standard definition. Furthermore, an editorial by Behr (2004) postulated that, in a mixed 
population, the resistant strain would be selected through antibiotic treatment, ultimately leading 
to dominance of the resistant strain and poor treatment outcome (Behr, 2004). This was 
confirmed in several subsequent studies where patients were dually infected prior to treatment, 
but the proportion of the resistant strain was initially too low to be detected by traditional 
molecular methods. However, after receiving treatment, an increase of the resistant strain was 
observed due to antibiotic selection (van Rie et al., 2005; Streicher, Bergval, et al., 2012; Eldholm 
et al., 2014; Mayer & Takiff, 2014). These studies also showed that following the withdrawal of 
antibiotic pressure, the drug susceptible population reappeared, suggesting that the drug 
susceptible population was more fit than the drug resistant population (van Rie et al., 2005; 
Streicher, Bergval, et al., 2012; Eldholm et al., 2014; Mayer & Takiff, 2014). Van Rie et al. (2005) 
used highly sensitive PCR based methods to describe the M. tuberculosis strain population 
structure in serial clinical isolates to determine the mechanisms whereby drug resistance 
emerges in a patient over time (van Rie et al., 2005). Three mechanisms were identified, namely 
acquisition of resistance after prolonged therapy, reinfection and mixed infection (van Rie et al., 
2005), which was also confirmed by other studies (Hofmann-Thiel et al., 2009; Sun et al., 2012). 
All of these scenarios may have resulted in heteroresistance, posing a diagnostic challenge if the 
minority population was drug resistant. 
The low sensitivity of current diagnostic methods to accurately predict the presence of resistant 
subpopulations may lead to diagnostic confusion, especially when serial isolates show different 
resistance patterns when the susceptible population re-emerges after withdrawal of the therapy, 
which could subsequently impact therapy and therapeutic response. Information regarding the 
presence of heteroresistant populations may be vital when considering the pharmacogenetic 
implications of the different drug resistance causing mutations as well as transmission prevention 
strategies. Alternatively, diagnostic delay, e.g. a 4 to 8 weeks turn-around time for phenotypic 
DST, causes a clinical dilemma of which regimen to start the patient on, limiting future treatment 
options if patients are incorrectly treated. For instance if a patient starts treatment with first-line 
drugs while awaiting diagnostic outcome, ineffective treatment (due to the inability to detect 
underlying resistance to either INH or RIF) could pose a risk of amplification of resistance to 
pyrazinamide and ethambutol (van Rie et al., 2013). Under these conditions the patient may still 
be infectious, which could subsequently lead to transmission of the resistant or susceptible TB 
strain and/or poor treatment outcomes (van Rie et al., 2005, 2013). On the other hand, not 
starting treatment with any drug poses infection control issues and increased risk of death (van 
Rie et al., 2005, 2013). It is for these reasons important to note that incorrect TB treatment of 




undetected heteroresistance can lead to limited treatment options and propagation of undetected 
resistant or susceptible strains. 
A foreseeable solution will be the implementation of higher-resolution sequencing methods that 
can be applied directly to sputum samples to overcome some of the above mentioned 
confounders that play a role in heteroresistance detection. In addition, high resolution sequencing 
diagnostic tests can provide insight into within host complexity of infection and the dynamic 
response of the organisms under the selective pressure of treatment (Cohen et al., 2016). 
Limitations of different diagnostic methods 
Diagnosing heteroresistance is challenging, with many factors playing a role in detection of 
heteroresistance. The primary reason is failure to harvest all existing variants within a patient’s 
sputum sample. This may occur through loss of rare variants during sample transport or 
decontamination (Rinder, 2001), during the DNA extraction procedure. Alternatively, the ratio of 
heteroresistant variants may be altered during culturing when subpopulations may outcompete 
each other (Cohen et al., 2016) or may be lost during culturing in the presence of an antimicrobial 
agent (Streicher, Bergval, et al., 2012; Zhang, Lu, et al., 2014; Colman et al., 2015). Additional 
challenges that influence the detection of heteroresistance in M. tuberculosis are the different 
mutations conferring resistance to a single anti-TB drug, necessitating sequencing of more than 
one genomic region (Colman et al., 2015). Furthermore, the detection of heteroresistance also 
depends on the sensitivity of the molecular technique used in a study, since the current 
molecular techniques have variable detection limits for detection of low frequency underlying 
genomic mutations conferring drug resistance. Alternatively, culture-based phenotypic DST is a 
more accurate and sensitive diagnostic technique, especially when the mechanism of action is 
unknown and is currently considered as the gold standard for DST (WHO, 2014). However, The 
limitations of culture-based phenotypic DST are that it is very time consuming (4 to 6 weeks from 
receipt of clinical samples), and requires a very good infrastructure and trained personnel, which 
is costly (Tolani et al., 2012). 
NGS-based diagnostic methods are also costly and require highly advanced technology and 
expertise. Furthermore, unknown resistance-conferring mutations may be overlooked, targeted 
deep sequencing platforms possess intrinsic sequencing error rates, possibly obscuring true 
variants, and stochastic PCR effects will alter resistant allele frequencies (Rinder, 2001; Colman 
et al., 2015). The latter, refers to the initial DNA amplification step, a confounder that affects all 
culture-independent molecular resistance prediction tests, which all consequent steps rely on 
(Rinder, 2001). 
In addition, the available methods to detect heteroresistance are non-standardized methods that 
are costly, vary in their detection abilities and are resource dependant and labour intensive, 




indicating that these factors are preventing the evaluation of the severity and clinical magnitude 
of this phenomenon, and prevents implementation of proper guidelines and therapeutic 
interventions (El-Halfawy & Valvano, 2015). Furthermore, the clinical relevance of variants in less 
than 1% of the population still needs to be determine. 
Outstanding questions 
Significant progress has been made in TB research, more specifically discovering 
heteroresistance, determining some of the causes of heteroresistance, and establishing which 
methods are appropriate to diagnose heteroresistance. However, more research is required as 
many more questions have been raised, some of which can form the basis of future studies. For 
example, to determine which of the following occur more frequently, (I) acquisition or (II) infection 
with mixed strains. Alternatively, future studies can show the clinical relevance of 
heteroresistance in a carefully designed experiment or determine at what point the drug regimen 
needs to change. Furthermore, in a comparative study of diagnostic techniques, a particular 
diagnostic technique could be highlighted that is sensitive and accurate enough to detect 
heteroresistance in all of the M. tuberculosis lineages. Alternative studies could indicate how the 
decontamination step carried out before starting the culture affects the heteroresistant 
populations and show the percentage of organisms that gets lost during the decontamination 
step. It will also be very interesting to prove that underlying variants (e.g. 0.1%) can result in 
clinical drug resistance. Novel methodologies are needed to allow targeted deep sequencing to 
be done directly from sputum specimens. Currently the effect of the decontamination step carried 
out before culturing of hetero-resistant populations is unknown (Rinder, 2001). Finding answers 
and solutions to the pressing challenge of heteroresistance might significantly impact TB 
research and assist in prevention and management of the disease. 
Conclusion 
The clinical outcome of MDR-TB cases remains poor, with an estimated 50% treatment success 
(completion or cure) globally (WHO, 2015a). A contributing factor is heteroresistance, which 
exacerbates poor clinical outcomes (El-Halfawy & Valvano, 2015). In addition, current genetic 
DSTs are only able to detect underlying resistance if the proportion of resistant clones (strains) 
are ≥5% (Engström et al., 2013; Folkvardsen, Thomsen, et al., 2013) resulting in an 
underestimation of the true prevalence of heteroresistance. The low sensitivity of these and other 
molecular methods compared to culture, cause it to be used as “rule in” assays and should be 
supplemented with phenotypic testing to identify the emergence of resistant clones during 
treatment.  
Ideally, molecular methods should be able to accurately detect the presence of ≤1% underlying 
populations prior to advising treatment or in order to identify the emergence of resistant clones 




during treatment. However, as discussed in this review, the current diagnostic methods have 
variable M. tuberculosis detection abilities and are limited to detect a certain percentage of 
resistant M. tuberculosis strains. Targeted NGS is currently the most advanced and powerful tool 
to detect underlying populations (Faino & Thomma, 2014). Targeted deep sequencing has been 
used extensively in the field of human immunodeficiency virus (HIV) and has the potential to 
become the next gold standard molecular diagnostic tool for the detection of underlying 
populations (Li & Kuritzkes, 2013) as its detection limit is similar to that achieved by culture 
based methods. However, currently diagnostic methods, based on NGS technology are being 
streamlined to shorten the turnaround time in order to obtain results instantly.  
The prospect of implementing targeted deep sequencing as a routine clinical diagnostic could 
potentially provide early detection of antibiotic resistant subpopulations (heteroresistance). 
Targeted deep sequencing could thus be used to detect resistance-associated variants at low 
frequencies prior to implementation of treatment or during treatment, allowing the prescription of 
tailored treatment regimens. In turn, this could potentially prevent the selection of resistant 
populations, improve treatment outcome and prevent the consequent transmission of resistant 
strains.  




Chapter 3: Materials and Methods 
Sample selection and DNA extraction  
Three different types of Mycobacterium tuberculosis DNA samples were used in this study, 
namely (I) purified DNA extracted from a gyrA-wild type (H37Rv) and -mutant (BO1) isolate 
(which was also used to make synthetic heterogeneous mixtures), (II) crude DNA extracted from 
heat inactivated cultured M. tuberculosis isolates, and (III) crude DNA extracted from 
decontaminated sputum specimens using the GenoLyse kit (Hain Lifescience, Germany) as well 
as crude DNA extracted from heat inactivated MGIT cultured M. tuberculosis isolates 
(I) The purified DNA used in this study was extracted from cultures of two strains housed at the 
Department of Biomedical Sciences, Stellenbosch University, namely the M. tuberculosis H37Rv 
laboratory isolate and an in vitro selected ofloxacin-mono resistant M. tuberculosis isolate (BO1). 
BO1 harbours the following polymorphisms in gyrA: GAG21CAG, GAC94GGC, AGC95ACC, 
GGC668GAC, and no polymorphisms in gyrB. The gyrA GAC94GGC mutation is known to confer 
resistance to fluoroquinolones (Chakravorty et al., 2011). These isolates were previously 
characterised with standard DST and whole genome sequencing (McGrath et al. 2016). DNA 
was extracted using the phenol chloroform method as previously described (Warren et al., 2006). 
The M. tuberculosis cultures were heat inactivated by incubating the culture plates in a pre-
heated oven at 80°C for 2 hours. The bacteria were then harvested by scraping the bacteria off 
from the media using a sterile disposable 10 µl plastic loop and placing the bacteria directly into a 
50 ml polypropylene centrifuge tube containing 20 x 5 mm glass beads and 6 ml extraction buffer 
(5 % sodium glutamate, 50 mM Tris-HCl (pH7.4) and 25mM EDTA). The bacterial colonies were 
dispersed by vigorous vortex mixing for 2 min. Five hundred microliter (500 µl) of lysozyme 
(25mg, Roche, Germany) at a concentration of 100 mg/ml was then added to each bacterial 
suspension and incubated at 37°C for 2 hours to degrade the cell wall and to digest RNA. 
Subsequently, 600 µl of 10X Proteinase K buffer (5% sodium dodecyl sulphate, 100nM Tris-HCl 
(pH 7.8), 50mM EDTA) together with 1.5 mg proteinase K (150 µl of a 10mg/ml stock solution) 
was added and the suspension was incubated at 45°C for 16 hours to digest all bacterial 
proteins. Thereafter, 5 ml phenol/chloroform/isoamylalcohol (24:23:1) was added and gently 
inverted every 30 minutes (min) for 2 hours at room temperature. Each tube was then centrifuged 
at 3000 revolutions per min (rpm) for 20 min at room temperature to ensure complete phase 
separation. The aqueous phase was carefully transferred to a new 50 ml polypropylene 
centrifuge tube which contained 5 ml of chloroform/isoamyl alcohol (24:1), followed by gentle 
mixing by inversion and centrifugation at 3000 rpm for 20 min at room temperature. The aqueous 
phase was carefully aspirated and transferred to a new 50 ml polypropylene centrifuge tube 
containing 600 µl 3M sodium-acetate pH 5.2. To precipitate the DNA, 7 ml of ice-cold isopropanol 




was added and the tube was gently inverted. The precipitated DNA were collected immediately 
on a thin glass rod and incubated for 10 min in a 1.5 ml tube containing 1 ml 70 % ethanol. The 
glass rod with precipitated DNA was then transferred to a new 1.5 ml tube and allowed to dry at 
room temperature. Subsequently, the DNA was rehydrated by adding 300 µl Tris-EDTA (TE) 
buffer (10mM Tris-HCl (pH 8.0), 1mM EDTA), followed by gentle mixing. The DNA was incubated 
at 65°C for 2 hours to allow for the DNA to re-dissolve. The DNA concentration was determined 
using the NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA).  
The synthetic heterogeneous mixtures (with the ratios ranging from 100% mutant to 0% mutant) 
(Table 1) were prepared by adding a constant volume of purified BO1 mutant DNA (2.5 µl) to 
different volumes of purified H37Rv wild type DNA. The purified mutant DNA concentration was 
used to determine the volume of purified wild type DNA needed to make synthetic heterogeneous 
mixtures at an expected percentage (%), e.g. a 10 % mutant DNA sample (i.e. 90:10 ratio). A 
nanodrop reading was taken of each mixture and the mixture was diluted to a final DNA 
concentration of 25 ng/µl. Subsequently a 10-fold serial dilution of the heterogeneous mixtures 
was made using TE buffer (ranging from 25 ng/µl to 25x10-6 ng/µl DNA concentration). A DNA 
concentration of 25x10-6 ng/µl is approximately equivalent to 5 copies of DNA template (see 
Appendix B). This was done to test the sensitivity of the PCR amplification method used in this 
study. 
(II) A total of eleven serial isolates from three patients (see Table 1) showing the acquisition of 
fluoroquinolone (FQ) resistance were selected from a longitudinal M. tuberculosis strain bank 
housed at the Department of Biomedical Sciences (Study: “Fluoroquinolone resistance in 
patients with multidrug-resistant tuberculosis study” (N1 /0 /106)). Crude DNA was extracted 
from the selected isolates by incubating an aliquot (200 µl) of the cultured isolate at 100 °C for 
30min. The boiled isolates were then centrifuged and the supernatant was aspirated into a clean 
eppendorf tube. 
(III) A total of eleven serial culture confirmed isolates (base line and follow up) from five patients 
collected during the OptiQ Phase 2 clinical trial (Efficacy and Safety of Levofloxacin for the 
Treatment of Multi-Drug Resistant Tuberculosis, Opti-Q; NIAID U01AI100805-02) were selected. 
Patients that participated in this trial received various dosages of levofloxacin in combination with 
the standard MDR regimen. This collection included baseline FQ susceptible MDR-TB isolates as 
well as follow up isolates collected between week 8 and 16 (see Table 1). Crude DNA was 
extracted from the baseline sputum specimens using the GenoLyse kit (Hain Lifescience, 
Germany) according to manufacturer’s instructions. In addition, crude DNA was extracted from 
the 8 to 16 week follow-up MGIT cultured isolates using heat inactivation as described above. 




The latter method was used to determine whether the resistant clones that emerge on therapy 
were initially present and was simply selected for under antibiotic pressure or whether they 
emerged as the result of a mutation while on treatment. 
A clinical isolate R2658 was used as a positive control to validate the NGS data analysis pipeline. 
Isolate R2658 was chosen because it has been characterized by targeted deep sequencing (on 
the Illumina MiSeq 2x300bp platform) in a previous study. Therefore the results generated in this 
study can be compared to what was found in the previous study. Targeted deep sequencing of 
the R2658 clinical isolate (work that was done previously) revealed that it had multi-drug 
resistance conferring mutations in katG315 (AGC to GGT) and rpoB531 (TCG to TTG), as well 
as FQ resistant conferring mutations in gyrA94 (GAC to GGC) at a variant frequency of 44.5% for 
GGC (the minor component). 




Table 1 A description of the different clinical isolates used in this study. 










BO1 (mutant) Ratio WT:MU 
(0:100) 
NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Not sequenced 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 








NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 




NA Yes Ion Torrent PGM 
& Illumina MiSeq 
H37Rv Ratio WT:MU 
(100:0) 
NA Yes No 




1st clinical isolate 05/01/2010 Yes Illumina MiSeq 





1st clinical isolate 28/08/2009 Yes Illumina MiSeq 
2nd clinical isolate 02/10/2009 Yes Illumina MiSeq 
3rd clinical isolate 27/10/2009 Yes Illumina MiSeq 




1st clinical isolate 29/07/2010 Yes Illumina MiSeq 
2nd clinical isolate 23/09/2010 Yes Illumina MiSeq 
3rd clinical isolate 25/10/2010 Yes Illumina MiSeq 




27/01/2016 Yes Illumina MiSeq 
Week 8 clinical 
isolate 






01/06/2015 Yes Illumina MiSeq 
Week 8 clinical 
isolate 
22/08/2015 Yes Illumina MiSeq 
Week 10 clinical 
isolate 





08/03/2015 Yes Illumina MiSeq 
Week 16 clinical 
isolate 
01/07/2015 Yes Illumina MiSeq 








25/05/2016 Yes Illumina MiSeq 
Week 8 clinical 
isolate 





24/02/2015 Yes Illumina MiSeq 
Week 8 clinical 
isolate 





Fluoroquinolone (FQ). Wild type (WT):Mutant (MU). 






Primer3Plus (Untergasser et al., 2007) was used to design primers for the amplification of 
the QRDR region of gyrA and gyrB, with product sizes not greater than 300 base pairs in 
length (Appendix Table A 1). The length of the amplicon plays an important role in 
determining the amount of sequencing coverage that can be generated per sample as the 
sequencing technology used in this study was limited to 300 bp reads. In addition, we 
evaluated the amplification efficiency of previously designed primers (Chakravorty et al., 
2011 and Colman et al., 2015) (Appendix Table A 1). Each primer sequence was then 
compared to the reference sequence making use of the Basic Local Alignment Search Tool 
(BLAST) on the NCBI database, to determine whether the designed primers had multiple 
binding sites elsewhere in the genome of M. tuberculosis (NCBI, 1997). Primer sets selected 
for this study are shown in Table 2, all of which provided reliable, specific and efficient 
amplification of the target regions. The primer sets were either used in a mono-plex PCR 
reaction when only one of the primer sets were present in the reaction (during testing for the 
efficiency of amplification), or used in a duplex PCR reaction where both primers sets were 
present in the reaction (during testing for the efficiency of amplification as well as during 
amplification for Sanger sequencing and Targeted deep sequencing). 





Name of primer set Gene Forward primer Reverse Primer Size 
(bp) 
*Primer set A gyrA 5’-gggtgctctatgcaatgttcgat- ’ 5’-gggcttcggtgtacctcatc- ’ 237 
Primer set B gyrB 5’-accgacatcggtggattg- ’ 5’-gatatcgaactcgtcgtggat- ’ 261 
*Primer set A described by Colman et al., 2015 





The optimized PCR conditions were as follows: The PCR protocol was according to Colman 
et al. (2015), with the exclusion of 5 µl Betaine solution (Appendix Table A 5). The 25 µl 
PCR reaction consisted of the following reagents: 9 µl Nuclease-Free water (Ambion), 12.5 
µl Q5 Hot Start High-Fidelity 2X Master Mix (The Q5 Hot Start High-Fidelity 2X Master Mix 
contains: dNTPs, 2 mM Mg++, proprietary broad-used buffer, and hot start DNA polymerase 
with  ’ – 5’ exonuclease activity (New England Biolabs Inc.), 10 µM forward primer (1.25 µl), 
10 µM reverse primer (1.25 µl), and 1 µl pure DNA (at a concentration of 25 ng/µl). A volume 
of 2 µl was used for DNA samples extracted using the GenoLyse kit. To reduce primer dimer 
formation, the primer concentration was decreased to 0.4 µM forward primer (0.05 µl) and 
0.4 µM reverse primer (0.05 µl), these concentrations were also used for the duplex PCR. To 
compensate for the decreased primer volumes we also increased the volume of Nuclease-
free water (Ambion) to 11.5 µl (Appendix Table A 1). The thermocycling conditions for 
cultured sample were as follows: an initial denaturation at 98ºC for 1 min, followed by 35 
cycles of denaturing at 98ºC for 10 sec, annealing at 60ºC for 15 sec, and extension at 72ºC 
for 20 sec and a final extension at 72ºC for 2 min (Protocol for Q5® Hot Start High-Fidelity 
2X Master Mix (New England Biolabs Inc.)). To improve the efficiency of amplification, the 
number of cycles was increased to 45 cycles with the annealing temperature increased to 62 
ºC (for 15 sec) when using crude DNA (extracted using the GenoLyse kit) as template 
(Appendix Table A 2 and - Table A 3). Each procedure was conducted in a separate room 
to minimise the risk of cross-contamination. RNase-free water was used as a negative 
control to regulate for reagent contamination. 
Electrophoretic evaluation 
A 1.5% agarose solution was prepared by dissolving 1.5 g of agarose in 100 ml of 1x tris 
base acetic acid ethylene diamine tetra acetic acid (TAE) buffer (pH 8.0) and heating the 
solution in a microwave oven until fully dissolved. Once the mixture has cooled, 5 µl 
ethidiumbromide (10 mg/ml) was added to the solution casted into a gel tray and allowed to 
cool to room temperature. A 5 µl aliquot of the PCR products (25 µl) were mixed with 1 µl 
loading dye (0.25% Xylene Cyanol, 30% glycerol) and was loaded onto the gel. The size of 
the amplified DNA samples were determined by a 100 bp Plus DNA ladder (GeneRuler, 
Thermo Scientific, USA) that was loaded into a well adjacent to the samples. The gel was 
run at 100 V for approximately 3-4 hours in 1x TAE buffer and visualized under ultra violet 
light using the Experion automated electrophoresis system. To avoid any form of amplicon 
contamination, all PCR reactions were done in duplicate. The opened PCR tube (containing 
the remaining 20 µl PCR product) was send for Sanger sequencing and only PCR products 




from closed PCR tubes were send to Central Analytical Facility (CAF) or Agricultural 
Research Council (ARC) for next generation sequencing. 
Sanger sequencing 
The PCR products were subjected to post PCR manual bead clean-up and sequenced with 
only the forward primer from primer set A using Sanger Sequencing at the Central Analytical 
Facility (CAF), Stellenbosch University. The reason is that variants are found to occur in 
gyrA more often and seldom in gyrB. The sequencing files received from CAF were aligned 
to the M. tuberculosis H37Rv laboratory reference sequence using DNAMAN (Lynnon, 
Quebec, Canada), while Chromas version 2.4 (Technelysium, Australia) was used to visually 
inspect the chromatograms of the sequences for underlying variants which are represented 
by double peaks on the chromatogram file.  
Targeted deep sequencing of isolates 
Ion Torrent and Illumina were used as the two sequencing platforms to investigate the 
presence of underlying fluoroquinolone resistant populations in the DNA isolated from the M. 
tuberculosis isolates selected for the present study, which were subjected to targeted deep 
sequencing. Unpurified PCR products were submitted to the relevant sequencing facilities, 
namely CAF (for sequencing on the Ion Torrent platform) and ARC (for sequencing on the 
Illumina platform) for library preparation. During the library preparation, indexing adapters 
were ligated to the DNA fragments to allow for samples to be pooled on a sequencing run. 
The depth of the coverage for all isolates was estimated to be at least 60000 times to ensure 
a high level of confidence for identifying low frequency variation in the genes of interest. 
Ion Torrent sequencing was done using the Ion 318 semiconductor chip on the Ion Torrent 
Personal Genome Machine (PGM) System (Life technologies, California, USA). Two target 
regions (237bp QRDR of gyrA and 261bp QRDR of gyrB) of the 10 synthetic heterogeneous 
mixes, ranging from 0% to 10% mutant (Table 1). An amplicon library was prepared prior to 
sequencing using the Ion Amplicon Library Preparation (Fusion Method) protocol at CAF. 
The Illumina MiSeq platform using the 2x300bp version 3 sequencing chemistry (Illumina, 
California, USA) was used for targeted deep sequencing on (I) the 10 synthetic 
heterogeneous mixtures (ranging from 0% to 10% mutant), (II) crude DNA extracted from 
serial patient isolates displaying the acquisition of fluoroquinolone resistance and (III) crude 
DNA extracted from serial patient isolates receiving levofloxacin at different dosages in a 
clinical trial (Table 1). TruSeq Nano DNA Library Prep guide was used for the library 
preparation. 




Bioinformatic analysis  
Ion Torrent data analysis 
The BAM files generated by the Ion Torrent PGM platform was analysed by the Torrent Suite 
4.0 on the Torrent Server (http://github.com/iontorrent/TS) at CAF. DNA sequences were 
aligned to the reference genome M. tuberculosis H37Rv. The generated BAM data files of 
the targeted deep sequenced synthetic heterogeneous mixtures of M. tuberculosis isolates 
were provided by CAF and were shared via a secure file transfer protocol (FTP). 
Subsequently, variants were called using the stand alone Torrent Variant Caller Plugin 
(ThermoFisherScientific, 2013). The variants called by the Ion Torrent Variant Calling 
Algorithms are based on the consensus accuracy which is independent of the variants 
identified in raw reads. The specific Ion Torrent Variant Calling parameters were adjusted as 
follows: (1) the duration of time ("wall time") the torrent server spends on a plugin was 
increased from 96 hours to 960 hours to ensure completion of the analyses and (2) the 
coverage ("downsample_to_coverage") was increased from 2000 times coverage (the 
default) to 60000 times coverage. The resulting files were provided in a variant caller format 
(VCF). The VCF file, is a tab-separated file that contains information regarding the position, 
alternative allele observations, read depth at the locus (coverage) and quality score in phred 








Illumina data analysis 
The fastq targeted deep sequence data files of the sequenced M. tuberculosis isolates were 
provided by the ARC and were shared via a secure FTP. A computational program, md5sum 
was used to verify if the raw sequenced data files (fastq files) were completely downloaded 
and similar to the files on the FTP site. Computational analysis was done using the protocol 
described by Colman et al. (2015) (Colman et al., 2015). 
The workflow for data analysis of targeted deep sequences on the Illumina platform is 
summarised in Figure 2.  
 
Figure 2 Outline of the computational analysis of targeted deep sequencing data. SAM: 
Sequence Alignment/Map format, BAM: Binary alignment format. SMOR: Single molecule-
overlapping reads analysis, SNPS: Single-nucleotide polymorphism. 
 









Alignment to a reference genome 
Convert SAM to BAM, mapping statistics 
Post alignment processing of the bam file 




FASTQ file format 
Biological sequences and the corresponding quality information recorded from the 
sequencer are stored in a text-based format (i.e. fastq format) comprising of four lines. The 
first line begins with a "@" character and is followed by a sequence identifier. The second 
line gives the raw sequence letters. The third, optional line starts with a "+" character and is 
optionally followed by the same sequence identifier. The fourth line encodes the phred 
quality value of the sequence, with one character pertaining to each base in the second line 





Figure 3 An example of a read from a fastq file generated by the Illumina sequencing. 
Phred quality score 
Sanger and Illumina phred quality scores (Q) are depicted as American standard code for 
information change (ASCII) characters with an offset of +33. Each character in Line 4 of a 
fastq file is correlated with a number. For example, the character "C" (Line 4 in Figure 3) 
represents a phred quality score (Q) of 34 that correlates to an error probability of 0.00040, 
which means that the quality of the base scored was high.  
NGS sequencing technologies generate phred scores that are assigned to each nucleotide 
base called in an automated sequencing run (Cock et al., 2010). A phred score is 
logarithmically linked to the error probability of a base called, e.g.    -10 log
10
 P, where: Q 
is equivalent to phred score and P is equivalent to error probability. 
A high base accuracy is represented by a phred score of >10. If a base has a phred score of 
10 it means that the probability of an incorrect base call is 1 in 10, resulting in a base call 
accuracy of 90%. 
Quality control 
The quality of the raw sequenced data for each isolate analysed was assessed with FastQC 
software (Babraham Institute, UK) using the generated fastq files. FastQC is a java-based 
program that evaluates various aspects of the raw data and produces the results in HTML 
(HyperText Markup Language) format (Consortium, 1999). The FastQC analysis is a 7 step 













the type of input file, the amount of reads processed, read length, and percentage GC 
content, II) calculates per read quality score by making use of the mean scores of all the 
reads, III) calculates the per base sequence content to determine the distribution of the four 
nucleotides throughout the reads, IV) calculates the GC content throughout the reads and 
comparing it to a theoretical normal distribution and mean value, V) calculates the possibility 
of contamination in the reads, VI) calculates the number of uncalled bases throughout the 
reads (number of "N"s), and VII) calculates the amount of duplicate sequences. A detailed 
FastQC report is generated from the results which provides a warning if quality scores are 
below that of the pre-set parameters. 
Read alignment to the reference genome 
Novoalign (Needleman-Wunsch algoritm) (Novocraft Technologies 
http://www.novocraft.com) mapping software were used to accurately map short sequencing 
reads (in the fastq format) to an indexed reference genome, M. tuberculosis H37Rv. 
Indexing of the reference genome was done by the "novoindex" command, using a k-mer 
indexing size of 13 and an indexing step size of 1. The fastq reads were used as input and 
the alignment was computed using the Needle-Wunsch algorithm. Novoalign software does 
global gapped alignment and for this analysis the default value of 6 was used, thus allowing 
six mismatches per alignment, producing an output in the Sequence Alignment/Map (SAM) 
format. The SAM format is compact in size, can be indexed (allowing for the efficient and 
fast retrieval of all the reads at a specific chromosomal locus. This format also allows most 
operations on the alignment to work on a stream without loading the entire alignment into the 
memory. 
Converting the SAM file to a BAM file 
SAMTools (http://samtools.sourceforge.net) provides a set of utilities for manipulating and 
post-processing of SAM files (Li et al., 2009). The software package includes tools to sort, 
merge, and index SAM files. The SAMTools commands "view" and "sort" was used to 
convert the SAM alignment files into a sorted binary alignment (BAM) format. Likewise, 
SAMTools was used to assess the percentage mapped reads using the "flagstat" function. 
Variant calling 
An independent variant caller was used to identify SNPs with regards to the reference 
genome used for the alignment. The mapping file obtained from the previous step was 
analysed with a SNP caller, single molecule-overlapping reads analysis (SMOR) (DePristo et 
al., 2011; Colman et al., 2015). The resulting variants are given in the variant call format (vcf) 
file format. The variant caller was used to detect underlying variants present in deep 
sequenced data. 





The SMOR analysis script (https://github. com/TGenNorth/SMOR)(Colman et al., 2015) was 
used to call the frequency of each nucleotide present at each position in the sequence. The 
SMOR script (paired_haplotype_smor.pl found at https://github.com/TGenNorth/SMOR) is 
preloaded with a set of amplicon identifiers and gene positions that are known to confer 
resistance to anti-TB drugs. Additional gene targets or gene positions can be added. 
Alternative gene targets or gene positions can also be removed from the SMOR script, which 
will allow for an unbiased variant calling approach. The script accepts a BAM file as input, 
and searches the file for complete overlap of the forward and reverse paired-end reads from 
the same DNA molecule, calculating the total frequency at which each nucleotide appears at 
a certain position in single- and paired reads. The information is presented in a table of 
counts for each position of interest, e.g. the output text file contains the position of interest, 
the number of times a nucleotide is called by a pair of reads, the total coverage, as well as 
the total number of times a nucleotide is called by a single read. 
For analysis purposes the QRDR regions of gyrA and gyrB were targeted in M. tuberculosis 
which contains drug resistance conferring SNPs. The entire QRDR of both gyrA and gyrB 
(unbiased approach), as well as forty-five previously published SNP loci conferring 
resistance to ofloxacin (OFX) (Table 3) were examined during the SMOR analysis.  















Wild type Mutant 
gyrA 88 GGC-TGC 7563-7565 7563 G T 
gyrA 88 GGC-GCC 7563-7565 7564 G C 
gyrA 89 GAC-AAC 7566-7568 7566 G A 
gyrA 90 GCG-G(A/G/T)G 7569-7571 7570 C (A/G/T) 
gyrA 91 TCG-(C/G)CG 7572-7574 7572 T (C/G) 
gyrA 92 ATC-ATG 7575-7577 7577 C G 
gyrA 94 a GAC-(A/C/T)AC 7581-7583 7581 G A/C/T 
gyrA 94 b GAC-G(T/C/G)C 7581-7583 7582 A T/C/G 
gyrA 95** AGC-ACC 7584-7586 7585 G C 
gyrA 102 CCC-CAC 7605-7607 7606 C A 
gyrA 109 CTG-GTG 7626-7628 7626 C G 
gyrA 112** GGC-GGG 7635-7637 7637 C G 
gyrA 120** GGC-GGG 7659-7661 7661 C G 
gyrA 125** GCG-GCA 7674-7676 7676 G A 
gyrB 90 GCC-GGC 5507-5509 5508 C G 
gyrB 446 CGT-TGT 6575-6577 6575 C T 
gyrB 446 CGT-C(A/T)T 6575-6577 6576 C T 
gyrB 447 TCC-TTC 6578-6580 6579 C T 
gyrB 461 GAC-(A/C)AC 6620-6622 6620 G (A/C) 
gyrB 461 GAC-GCC 6620-6622 6621 A C 
gyrB 470 GGT-TGT 6647-6649 6647 G T 
gyrB 470 GGT-GCT 6647-6649 6648 G C 
gyrB 486 ATC-CTC 6695-6697 6695 A C 
gyrB 494 GAC-GCC 6719-6721 6720 A C 
gyrB 499 AAC-(T/G)AC 6734-6736 6734 A (T/G) 
gyrB 499 AAC-TAC 6734-6736 6735 A C 
gyrB 499 AAC-TAC 6734-6736 6736 C (A/G) 
gyrB 500 ACC-CCC 6737-6739 6737 A C 
gyrB 500 ACC-C(A/T)C 6737-6739 6738 C (A/T) 
gyrB 501 GAA-GTA 6740-6742 6741 A T 
gyrB 501 GAA-GA(T/C) 6740-6742 6742 A (T/C) 




gyrB 504 GCG-ACG 6749-6751 6749 G A 
gyrB 504 GCG-GTG 6749-6751 6750 C T 
gyrB 507 ACG-ATG 6758-6760 6759 C T 
gyrB 538 CAA-CA(T/C) 6851-6853 6853 A (T/C) 
gyrB 670 GTT-TTT 7247-7249 7247 G T 
 
** SNP does not confer resistance, possible position of interest or phylogenetic informative. 
See (Coll et al., 2015; Colman et al., 2015) for the SNP positions that confer antibiotic resistance. 




A pair of raw FastQ files (0.5% mutant frequency) 
at a coverage 472832 times 
Down sample fastq files a 
100x to a given coverage 
100 000 times 
coverage 
25 000 times 
coverage 




50 000 times 
coverage 
Down sampling of a synthetically created heteroresistant mixture 
To determine the minimum coverage needed to confidently detect extremely low frequency (<1%) 
gyrA variants, the total depth of coverage of a fastq file with a variant frequency of 0.5% and depth 
of coverage of 472832 times were down sampled in a step wise manner to 6250 times (Figure 4). 
Each down sampling step was repeated 100 times with the use of an automated in-house bash 
script (N.L. Da Camara, Department of Biomedical Sciences, Stellenbosch University) that allowed 
for the use of different seed numbers (i.e. prime numbers ranging from 300 to 5000) in order to 
generate "random" samples. The automated script made use of the seqtk tool 
(https://github.com/lh3/seqtk) for processing sequences in the FASTA and FASTQ format, in 
combination with an in house bash script (N.L. Da Camara, Department of Biomedical Sciences, 
Stellenbosch University) (see Appendix C). This resulted in the random generation of a 100 
different fastq files at the relevant depth of coverage (e.g. 100000 times coverage).  
 
Figure 4 Flow diagram showing down-sampling of sequenced data (fastq file) to a certain 









The work described in the present study forms part of a large on-going project which received 
ethical approval from the Stellenbosch University Health Research Ethics Committee under the 
title: ―Method development to detect minority fluoroquinolone resistant variants for predicting TB 
treatment failure: N16/04/049. 




Chapter 4: Results 
In order to determine the accuracy of the Illumina MiSeq and Ion torrent platforms identify 
underlying minority frequency variants in gyrA and gyrB, targeted deep sequencing was 
done using synthetic heterogeneous mixtures of a characterized wildtype (H37Rv) and 
ofloxacin resistant mutant (BO1). Subsequently, targeted deep sequencing (using the 
Illumina MiSeq platform) was used to investigate the presence of underlying variants in gyrA 
and gyrB in two groups of serial patient isolates: 1. Serial patient isolates collected that 
showed the acquisition of fluoroquinolone resistance, 2. Serial patient isolates collected from 
fluoroquinolone susceptible MDR-TB patients receiving different dosages of levofloxacin 
during a clinical trial. Lastly the study also investigated the minimum depth of coverage that 
is needed to detect underlying minority frequency variants. An outline of the sample 
selection and methodologies used in this study is showed in Figure 5.











Confirmed amplification of all 
samples 
Sanger sequencing of all the 
samples 
Deep sequencing of synthetically made 
heteroresistant samples using Ion Torrent 
Deep sequencing of all the samples using 
Illumina MiSeq 
Sample selection: 
(1) Synthetically made heteroresistant mixes ranging 
from 100% to 0% mutant. 
(2) Fluoroquinolone (FQ) resistant cultured DNA 
(3) GenoLysed (baseline sample) and boiled culture 
(8 to 16 week follow-up sample) 
Bioinformatic analysis 
Downsampling 





We first optimized the amplification of the QRDR of gyrA and gyrB in monoplex PCR 
reactions. Subsequently the amplification of both targets was optimized in a duplex PCR 
reaction, where the annealing temperature was decreased from 62°C to 60°C. In addition 
the number of reaction cycles was adjusted depending on the type of input DNA. It was 
found that 35 reaction cycles was efficient when using pure DNA or crude DNA extracted 
using the heat inactivation method and 45 reaction cycles where required using DNA 
extracted with the GenoLyse kit. A PCR efficiency test using quantitative Real-Time PCR 
and a ten-fold dilution series of purified H37Rv DNA showed that the efficiency of the 
amplification is equivalent for both primer sets used. 
We then tested the sensitivity of the duplex PCR reaction using a ten-fold serial dilution 
(from 25 ng/ul to 25x10-6 ng/ul) of a synthetic heterogeneous mixture with a mutant allele 
frequency of 10% as DNA template. As shown in Figure 6 the PCR product (with expected 
product sizes at 261bp for the QRDR of gyrB and 237bp for the QRDR of gyrA) using a 
starting template concentration of 25x10-6ng/µl were detected by gel electrophoresis and UV 
visualisation. In addition, underlying peaks of the resistant allele were visible on the 
chromatograms obtained from Sanger sequencing, shown in Figure 7, when using a starting 
template concentration of 25x10-5 ng/ul, which is equivalent to 52 copies of template DNA.  
 
Figure 6 Visualisation of PCR products of a ten-fold serial dilution of using wildtype H37Rv 
DNA as well as a synthetic heterogeneous mixture with a mutant allele frequency of 10% as 
DNA template. The expected product sizes of the PCR products were 261bp for the QRDR 
of gyrB and 237bp for the QRDR of gyrA. Lanes 1-7 shows the range (25 ng/ul to 25x10-5 
ng/µl) of the dilution series that was used as DNA template. Lane NC shows the negative 
control. Lane MW shows the GeneRuler 100 bp Plus DNA Ladder (GeneRuler, Thermo 









Figure 7 Sanger sequencing of synthetic heterogeneous mixture ranging from 100% to 0 % 
mutant, and vice versa) consisting of a DNA concentration of 10-5ng/µl, which is equivalent 
to 52 number of DNA copies. The DNA underwent PCR amplification and purified PCR 
products were Sanger sequenced. For example A) consist of 100%:0% denotes wild type 
(M. tuberculosis H37Rv) to mutant (FQ monoresistant strain (BO1)). B) 90%:10%. C) 
80%:20%. D 70%:30%. E) 30%:70%. F) 20%:80%. G) 10%:90%. H) 0%:100% 
  
A B C D 
E F G H 




Dilution series - Synthetically made heterogeneous mixes 
To test the sensitivity of the duplex PCR reaction and Sanger sequencing to detect 
underlying variants in the amplified targets of gyrA and gyrB, synthetic heterogeneous 
mixtures (ranging from 100% to 0 % mutant, and vice versa) were used as DNA template. 
Thereafter the Sanger sequencing chromatograms were visually inspected for the presence 
of underlying peaks (Figure 8). Underlying variants (i.e. heterogeneous) were identified by 
the presence of more than one peak at a single base position on the sequencing 
chromatogram. The limit of detection for Sanger sequencing was shown to be 6%, as no 
underlying peaks were detecting in samples with less than 6% mutant DNA (Figure 8). This 
is in agreement with previous studies (Folkvardsen, Svensson, et al., 2013; Pholwat et al., 
2013).






Figure 8 Sanger sequencing chromatograms of synthetic heterogeneous mixtures consisting of ratios of 
M. tuberculosis H37Rv:FQ mono-resistant strain (BO1), ranging from 100% mutant (top left corner) to 
0% mutant (bottom right corner) and from 0% wild type (top left corner) to 100% wild type (bottom right 
corner). Heteroresistance was identified by the double peaks at a single base position seen in the 
chromatograms. 
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Targeted deep sequencing of isolates (Ion Torrent PGM and 
Illumina MiSeq) 
Quality assessment of the fastq and alignment files. 
Synthetic heterogeneous mixtures  
The sequence quality per base of the forward read of all the mixtures were very good (phred 
score of 25 for 280bp of the read) with a decline in quality at the last 20bp of the forward 
read. However, the reverse read sequence quality was lower for the last 40bp of the read. 
Table 4 shows that an average of 404441 reads generated by the Ion Torrent platform and 
509765 reads generated by the Illumina MiSeq platform mapped to the M. tuberculosis 
reference genome, H37Rv when using TMAP and Novoalign as aligners respectively. Only 
reads with a quality phred score of greater than 20 (good) were allowed to map to the 
reference genome. The average read length of the reads was 209bp (using Ion Torrent) and 
300bp (using Illumina MiSeq). The average coverage at which variants were called was 








Table 4 Overview of the quantity (read coverage) of raw sequenced data of synthetic heteroresistant mixtures reads generated by the two 
different platforms, Ion Torrent Personal Genome Machine (PGM) and the Illumina MiSeq platform. Wild type (WT), mutant (MUT). 
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(Ion Torrent PGM) 
Coverage of reads 


















H37Rv & BO1 
(mutant) 
90:10 417406 432330 59913 157071 212 300 
H37Rv & BO1 
(mutant) 
92:8 294978 519192 18687 177551 187 300 
H37Rv & BO1 
(mutant) 
94:6 245319 544213 59921 205120 202 300 
H37Rv & BO1 
(mutant) 
96:4 543601 471204 59619 167255 213 300 
H37Rv & BO1 
(mutant) 
99:1 511031 503189 59773 186021 212 300 
H37Rv & BO1 
(mutant) 
99.2:0.8 378399 568886 57857 183776 212 300 
H37Rv & BO1 
(mutant) 
99.4:0.6 566221 461636 59915 170933 215 300 
H37Rv & BO1 
(mutant) 
99.5:0.5 347993 472831 51828 176022 213 300 
H37Rv & BO1 
(mutant) 
99.8:0.2 401252 516809 59915 205992 211 300 
H37Rv & BO1 
(mutant) 
99.9:0.1 338215 607364 44767 224909 216 300 
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Clinical M. tuberculosis isolates of three patients showing evolution of FQ 
resistance 
The average number of Illumina MiSeq reads that mapped to the M. tuberculosis reference 
genome, H37Rv, using Novoalign was 331574 (Table 5). The quality of the reads were 
extremely good with an average pherd score of greater than 34 per read. Variants were 
called at an average coverage of 114462 times using reads with a read length of 301bp. 
 
Table 5 Quantity (read coverage) of raw sequenced data of FQ resistant M. tuberculosis 
clinical isolates prior to bioinformatics analysis. 















1st clinical isolate 382130 117016 301 





1st clinical isolate 387236 
 
162655 301 
2nd clinical isolate 345390 136528 301 
3rd clinical isolate 345418 81089 301 




1st clinical isolate 280482 99420 301 
2nd clinical isolate 409253 134035 301 
3rd clinical isolate 278849 97222 301 
 
  




Clinical M. tuberculosis isolates from the OptiQ clinical trial of patients 
receiving FQ at different concentrations 
The average number of Illumina MiSeq reads that mapped to the M. tuberculosis reference 
genome, H37Rv, using Novoalign was 1892628 (Table 6). The quality of the Illumina MiSeq 
reads had an average phred score of greater than 34 per read indicative of high quality 
reads. Variants were called at an average coverage of 121450 times using reads with a read 
length of 301bp. 
 
Table 6 Quantity (read coverage) of raw sequenced data of M. tuberculosis clinical isolates 
from the OptiQ study, prior to bioinformatics analysis. 










OptiQ study  Patient 1 
 
Baseline clinical isolate 729108 38193 301 
  Week 8 clinical isolate 755884 58606 301 
 Patient 2 
 
Baseline clinical isolate 848516 53517 301 
  Week 8 clinical isolate 796732 58945 301 
  Week 10 clinical isolate 1035072 78944 301 
 Patient 3 
 
Baseline clinical isolate 823716 33735 301 
  Week 16 clinical isolate 1215724 105641 301 
 Patient 4 
 
Baseline clinical isolate 10947148 630140 301 
  Week 8 clinical isolate 758700 64225 301 
 Patient 5 
 
Baseline clinical isolate 980816 69883 301 
  Week 8 clinical isolate 763968 60864 301 
  




Comparison of variants called by different mappers, i.e. TMAP 
(Ion Torrent) and Novoalign (Illumina) for: 
Synthetically created heteroresistant mixtures ranging from 10% - 0.1% mutant 
Different frequencies of variants were detected in the TMAP and Novoalign pipelines, which can be 
attributed to the different technologies used by the two platforms and mapping algorithms used by 
each mapper. Table 7 shows the frequencies of variants detected for each synthetic heteroresistant 
mixture (ranging from 10% - 0.1% mutant) at an approximate coverage of 60000 time for Ion Torrent 
PGM deep sequenced data and at an approximate coverage of 185000 time for Illumina MiSeq 
deep sequenced data. Using this analysis method we were able to accurately detect subpopulations 
at 0.1% and above using the Illumina MiSeq platform. However, when using 60000 times coverage 
for the data generated by the Ion Torrent platform, only underlying variants with a frequency of 
greater than 2% could be detected. Ion torrent also did not detect the expected variant frequency at 
the input proportion. In contrast the Illumina MiSeq was able to detect variants at a similar proportion 
to the input. 
Table 7 Comparison of the variants called by the different mappers (TMAP and Novoalign) 
for synthetic heteroresistant mixtures, ranging from 10% - 0.1% mutant. 
 Variant frequency:  









H37Rv & BO1 (mutant) Ratio WT:MU 
(90:10) 
5% 9% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(92:8) 
5% 7% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(94:6) 
3% 5% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(96:4) 
2% 3% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(99:1) 
 0.91% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(99.2:0.8) 
 0.75% 
H37Rv & BO1 (mutant) Ratio WT:MU 
(99.4:0.6) 
 0.57% 
H37Rv & BO1 (mutant) Ratio WT:MU  0.41% 





H37Rv & BO1 (mutant) Ratio WT:MU 
(99.8:0.2) 
 0.17% 




Comparative analysis between Sanger sequencing and NGS 
SMOR analyses of targeted deep sequencing isolates 
Synthetically created heteroresistant mixtures ranging from 10% - 0.1% mutant 
Sanger sequencing was only able to detect underlying resistant subpopulations above 6% 
(Figure 9). Alternatively, SMOR analyses was able to detect a known mutant allele 
frequency of greater than 0.1% with and without filtering of known FQ resistant loci (Figure 
9). Figure 9 shows SMOR analyses at a certain heteroresistant ratio without (Figure 9, A1 
to A3) and with filtering (Figure 9, B1 to B3) known FQ resistant loci. 




A 1) A 2) A 3) 
B 1) B 3) B 2) Filtered 0.1% mutant 
Unfiltered 10% mutant Unfiltered 1% mutant Unfiltered 0.1% mutant 
Filtered 10% mutant Filtered 1% mutant 
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Figure 9 Illumina targeted deep sequencing results of the QRDR of gyrA gene from Synthetic heterogeneous mixtures, showing SMOR analyses at a certain 
heteroresistant ratio with and without filtering known FQ resistant loci. Allele position in the QRDR of gyrA (x-axis) vs allele percentage (%) (y-axis). A 1) 
SMOR unfiltered targeted deep sequencing results for the QRDR of gyrA showing the presence of underlying mutant variants at A 1) 10%, A 2) 1% and A 3) 
0.1%, B) SMOR filtered targeted deep sequencing results for the QRDR of gyrA, showing the mutant variants at A 1) 10%, A 2) 1% and A 3) 0.1%. 
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Clinical M. tuberculosis isolates of three patients showing evolution of FQ 
resistance 
Targeted deep sequencing was used to investigate serial patient isolates of three patients 
that showed the acquisition of FQ resistance by routine DST. As shown in Table 8, the first 
isolate for all three patients showed the absence of FQ resistance according to phenotypic 
DST, while the follow-up isolates showed the progression to pre-XDR TB.  
In Table 8 the following was observed: 
For Patient 1, two isolates were subjected to targeted deep sequenced. The first isolate 
(R8394) showed no variants above a frequency of 0.02% ("T" allele at codon 90 position 
7570 and "G" allele at codon 94 position 7582 were present at a frequency of 0.02%), 
suggesting that this isolate is wild type (Table 8). The second isolate (R9172) showed the 
acquisition of three underlying mutations (GCG90GTG, GAC94GGC in the QRDR of gyrA 
and GAC461AAC in the QRDR of gyrB) with variant frequencies of 3.35% (GCG90GTG), 
17.09% (GAC94GGC) in the QRDR of gyrA, and 0.16% (GAC461AAC) in the QRDR of gyrB 
(Table 8). 
Four isolates from patient 2 were analysed using Illumina-based targeted deep sequencing. 
The first isolate (R6747) showed the presence of an underlying variant (GCG90GTG) at 
0.17%, at a total depth of 162655 times coverage (Table 8 and Figure 10). The second 
isolate (R6971) showed an increase of the mutant allele (GCG90GTG) to 68.18% at a total 
depth of coverage of 136528 times. The frequency of the mutant allele (GCG90GTG) 
increases in the third isolate (R7515) to 86.14%, and to 98.63% in the fourth isolate with total 
depth of 81089 times and 87286 times coverage, respectively. A comparison of results of 
Sanger sequencing with Illumina targeted deep sequencing of clinical isolates from patient 2 
is shown in Figure 10. 
Four samples of patient 3 underwent Illumina MiSeq targeted deep sequencing. No variants 
were observed within the first isolate. In the second isolate, a mutant allele (GCG90GTG) 
was present at 99.91% at a total depth of 99420 times coverage. In the third isolate, the 
mutant allele frequency decreases to 98.60% at a total depth of 134035 times coverage. 
Interestingly, a second underlying variant is observed at a frequency of 0.07% in codon 
GAC94GCC with a total depth of coverage of 135026 times (Table 8). In the fourth isolate, 
six underlying variants are observed. The mutation GCG90GTG decreased to 41.59% with a 
coverage of 96862 times (Table 8). The mutation GAC94GCC increased from 0.07 to 1.33% 
at 96490 times coverage (Table 8). Furthermore, the additional underlying variants were 
observed in codons 88, 89, 91 and an additional underlying variant was observed in codon 
94. At codon 88, the mutant "T" allele (GGC88TGC) is present at 0.54% with a depth of 




coverage of 97909 times. Codon 89 has a depth of coverage of 97710 times with an 
underlying "A" mutant allele (GAC89AAC) at 0.96% (Table 8). Furthermore, a 9.07% 
underlying variant was observed in codon 91 (TCG91GCG) at 96674 times depth of 
coverage (Table 8). Lastly, the lowest underlying variant seen in this sample (R11603) was 
0.27%, a "C" mutant allele in codon 94 (GAC94CAC) (position 7581) present at a depth of 
coverage of 97688 times (Table 8).  
To determine the reproducibility of the Illumina MiSeq deep sequencing method we 
compared our results from the above clinical isolates to the results of a previous analysis on 
isolate R2658 done independently by Translational Genomics Research Institute (TGen). 
Illumina targeted deep sequenced confirmed the two mutant alleles in codon 94, the "C" 
(GAC94GCC) mutant allele that is present at 77.41% and the "G" (GAC94GGC) mutant 
allele that is present at 22.43% with a total depth of coverage of 78728 times (data not 
shown). The frequencies between the previous targeted deep sequenced and of the current 
study was very similar. Previously, 74.63% for GAC94GCC and 24.86% for GAC94GGC 
were obtained, compared to 77.41% for GAC94GGC and 22.43% for GAC94GCC. 
 




Table 8 Targeted deep sequencing results of clinical M. tuberculosis isolates showing 



















1st (R8394) 05/01/2010 FQ susceptible gyrA Wild type   
2nd (R9172) 23/03/2010 FQ resistant 
gyrA 
GCG90GTG 3.35 117016 
GAC94GGC 17.09 114914 
gyrB GAC461AAC 0.16 126187 
2 
1st (R6747) 28/08/2009 FQ susceptible gyrA GCG90GTG 0,17 162655 
2nd (R6971) 02/10/2009 FQ resistant gyrA GCG90GTG 68,18 136528 
3rd (R7515) 27/10/2009 FQ resistant gyrA GCG90GTG 86,14 81089 
4th (R7764) 27/10/2009 FQ susceptible gyrA GCG90GTG 98,63 87286 
3 
1st (R8569) 20/01/2010  Not targeted deep sequenced 
2nd (R10499) 29/07/2010 FQ susceptible gyrA GCG90GTG 99.91 99420 
3rd (R11193) 23/09/2010 FQ resistant 
gyrA GCG90GTG 98,6 134035 
gyrA GAC94GCC 0,07 135026 
4th (R11603) 25/10/2010 FQ susceptible 
gyrA GGC88TGC 0,54 97909 
gyrA GAC89AAC 0,96 97710 
gyrA GCG90GTG 41.59 96862 
gyrA TCG91CCG 9.07 96674 
gyrA GAC94CAC 0,27 97688 
gyrA GAC94GCC 1.33 96490 
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Figure 10 A comparison of results of (A) Sanger sequencing with (B and C) Illumina 
targeted deep sequencing of clinical isolates from Patient 2. A) Emergence of resistance 
(GCG90GTG) observed by the presence of underlying mutant peaks within the serial 
isolates (A 3). B1 to B4) Unfiltered targeted deep sequencing results for the QRDR of gyrA 
showing the presence of underlying variants, as well as the sequencing errors. C1 to C4) 
Filtered targeted deep sequencing results for the QRDR of gyrA that only shows the regions, 
which are known to contain resistant conferring SNPs. An underlying GCG90GTG variant 
can be observed at 17.09% (red circle). X-axis allele position in the QRDR of gyrA. Y-axis 
allele percentage in the QRDR of gyrA. 
Clinical M. tuberculosis isolates from the OptiQ clinical trial of patients 
receiving FQ at different concentrations 
We have applied the established Illumina MiSeq deep sequencing methodology to clinical 
isolates of patients receiving FQ at different concentrations in a clinical trial (OptiQ study) to 
determine whether resistance was present at baseline or develops during treatment. To 
achieve this, the first available (i.e. base line) isolate and the last available isolate (8 or 16 
weeks or 24 weeks) were selected for targeted deep sequencing. We were able to detect 
underlying variants GAC94GCC in the QRDR of gyrA within all the isolates (base line and 
follow-up) at 0.1% with an error rate of (0.1%) (Table 9), however no increase in frequency 
was observed for this variant in the follow-up isolates. No additional variants were observed 









Table 9 Targeted deep sequencing results of the clinical M. tuberculosis isolates from the OptiQ study. 
Study Patient Isolate 
designation 









OptiQ study Patient 1 
 
Baseline 27/01/2016 gyrA GAC94GCC 0.1% 38193 




Baseline 01/06/2015 gyrA GAC94GCC 0.06% 53517 
Week 8  22/08/2015 gyrA GAC94GCC 0.06% 58945 
Week 10  06/09/2015 gyrA GAC94GCC 0.08% 78944 
Patient 3 
 
Baseline  08/03/2015 gyrA GAC94GCC 0.07% 33735 
Week 16  01/07/2015 gyrA GAC94GCC 0.1% 105641 
Patient 4 
 
Baseline  25/05/2016 gyrA GAC94GCC 0.1% 630140 
Week 8  13/08/2016 gyrA GAC94GCC 0.07% 64225 
Patient 5 
 
Baseline  24/02/2015 gyrA GAC94GCC 0.09% 69883 
Week 8  14/05/2015 gyrA GAC94GCC 0.09% 60864 
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Downsampling was done to determine the minimum coverage required per sample to confidently 
detect 0.5% underlying mutant subpopulations. This was done to see if it is possible to make 
targeted deep sequencing a more economical approach by downsampling the depth of coverage 
while still ensuring detection of underlying mutant subpopulations. Detection of the underlying 
variant (GAC94GGC) was possible at all the various read coverages examined (from 1891328 to 
6250) with an average error rate of 0.41% (Table 10).  
 


















Raw read 472832 720 176022 0.41% 
Downsampling 100000 times 
coverage 
100000 153 37231 0.410% 
50000 times 
coverage 
50000 78 18616 0.421% 
25000 times 
coverage 
25000 38 9314 0.410% 
12500 times 
coverage 
12500 18 4659 0.396% 
6250 times 
coverage 
6250 11 2324 0.387% 




Chapter 5: Discussion 
In this study we explored the feasibility of using next generation targeted deep sequencing to 
identify underlying variants conferring FQ resistance. We found that targeted deep sequencing 
together with SMOR analyses is a more sensitive method to detect heteroresistance compared to 
the traditional diagnostic methods. Previous studies have shown that the GenoType MTBDRplus 
assay could only detect heteroresistant subpopulations if more than 5% of the resistant bacteria 
are present (Folkvardsen, Svensson, et al., 2013; Folkvardsen, Thomsen, et al., 2013), while Xpert 
MTB/RIF could only detect rifampicin resistance if more than 60% of the resistant bacteria are 
present (Blakemore et al., 2010; Engström et al., 2013; Folkvardsen, Thomsen, et al., 2013). 
Multiple studies have also showed that the detection limit of Sanger sequencing to identify of 
underlying variants is 10% (Folkvardsen, Svensson, et al., 2013; Eilertson et al., 2014; Colman et 
al., 2015). The current study showed that when sequencing at a very high (approximately 100000 
times) depth of coverage, underlying M. tuberculosis drug resistance conferring variants could be 
detected at frequencies as low as 0.5%. This approach could be applied in a clinical setting for 
early detection and monitoring of antibiotic resistant subpopulations, which could then potentially 
prevent selection of the resistant population and/or treatment failure that may occur if otherwise left 
undetected. However, when the list of variants produced by SMOR is filtered for only the known 
FQ resistance causing SNPs, we were able to identify variants at an underlying frequency of 0.1%. 
We were able to reproduce this sensitivity irrespective of the purity of the DNA sample, as this 
variant frequency was identified in purified DNA samples, crude DNA samples extracted from heat 
inactivated MGIT cultures as well as crude DNA extracted from sputum specimens. These findings 
confirmed our hypothesis that targeted deep sequencing can be used to identify underlying drug 
resistance causing variants in M. tuberculosis from clinical isolates.  
The highly optimised amplification-based approach using highly efficient primer sets for specific 
target regions made it feasible to detect underlying variants in samples with a low number of M. 
tuberculosis DNA copies, which is often the case in clinical samples (Colman et al., 2015). It is very 
important for the targets of the assay to be specific when used in a clinical setting, especially when 
using DNA directly extracted from sputum specimens (e.g. genolysed samples) which can also 
contain human DNA as well as DNA from other organisms. The primers used in the assay were 
found to be specific across a database of sequences and has a high PCR efficiency to detect the 
presence of M. tuberculosis.  
Underlying variants present at a variant frequency of more than 6% in the synthetic heterogeneous 
mixtures as well as in some of the clinical isolates used in this study could be detected by Sanger 
sequencing. This finding is in agreement with previous studies (Folkvardsen, Svensson, et al., 
2013; Zhang et al., 2014).  




When comparing the sensitivity of the Ion Torrent and Illumina MiSeq platforms for the detection of 
underlying variants in gyrA and gyrB using synthetic heterogeneous mixtures, we found that the 
Illumina MiSeq targeted deep sequencing was able to detect variants below a frequency of 1%. In 
contrast, targeted deep sequencing done by the Ion Torrent platform could only detect variants 
with a frequency of more than 2%. This is in agreement with a previous study that showed that 
Illumina is more suitable for detecting very low frequencies of variants than other platforms 
(McElroy et al., 2014). This may be due to the high sequencing error of Ion Torrent which limited 
our ability to identify underlying low frequency variants with confidence (Quail et al., 2012). In 
addition, the analysis of sequencing data produced by Ion torrent was problematic as one is 
confined to only use the Ion Torrent Suite which also has a slow processing time compared to the 
open source tools that are available for the analysis of Illumina sequencing data.  
Our analysis of the serial patient isolates progressing from MDR-TB to pre-XDR-TB showed that 
two different gyrA mutations were acquired in patient one after two months compared to the initial 
FQ susceptible isolate. The follow up isolate also showed the presence of a gyrB GAC461AAC 
mutation at 0.16% that is known to confer FQ drug resistance (Coll et al., 2015). This short time 
frame suggests that the bacteria are able to rapidly evolve when under a selective pressure 
(antibiotic treatment). An alternative reason may be that isolate 2 was sampled from an alternative 
lesion. 
Furthermore, we were able to show the presence of a low frequency FQ resistance conferring 
mutation (0.17%) in the first isolate of patient 2. The presence of the underlying FQ resistant 
population was however missed by standard DST due to the detection limit of the diagnostic tool. 
The frequency of this underlying mutant variant was found to substantially increase over time in the 
follow up isolates (Figure 10 or Table 8), which provided insight in the evolution of drug resistance 
among serial clinical M. tuberculosis isolates.  
Conversely, we were able to show in patient 3 the decrease of a high frequency mutation over 
time, with the acquisition of additional FQ resistance conferring mutations in the follow up isolates. 
This is in agreement with a previous study that found that heteroresistance allows for alteration of 
strain dominance according to the type of external threats that M. tuberculosis strains are exposed 
to (Streicher, Bergval, et al., 2012). Current TB treatment rely on treating TB infected patients with 
multiple drugs. This may efficiently suppress low level resistant causing variants present within a 
patient over time. Alternatively, combination therapy can compensate for each other when one 
drug is lost as a result of acquisition of resistance to it, or combination therapy can kill off clones 
containing the resistant mutant, thereby managing the TB burden and possibly prevent 
transmission of resistant strains.  
Discrepancies between targeted deep sequencing and phenotypic DST were found for the fourth 
isolate of patient 2 as well as in the second - and fourth isolate of patient 3 (Table 8). This may be 




attributed to incorrect phenotypic DST possibly due to the low level resistance that the mutation(s) 
cause with a minimum inhibitory concentration (MIC) very close to the critical concentration, as 
targeted deep sequencing shows the presence of the variants at very high frequencies (98.63% 
and 99.91%, respectively).  
The clinical M. tuberculosis isolates from the OptiQ study remained FQ susceptible, however 
shows underlying variants in codon 94 of gyrA (GAC94GGC) for all the clinical isolates (collected 
over a period of 8 weeks or 10 weeks or 16 weeks). This may be indicative of underlying FQ 
resistance in persisting M. tuberculosis strains that may slowly evolve to FQ resistant M. 
tuberculosis isolates as mutations found in codon 94 of gyrA gene is known to confer FQ 
resistance (Farhat et al., 2013).  
To compensate for the high cost of targeted deep sequencing, down sampling of the high coverage 
of the raw reads of 0.5% synthetic heterogeneous mutant were done to determine a more 
economical approach for detection of low frequency variants. We found that a minimum coverage 
of 6250 times is adequate to detect 0.5% underlying frequency variant. This is in agreement with 
Colman et al. (2015) that suggest a minimum of 1000x of paired reads (2000x total coverage) is 
needed in order to detect a 1% subpopulation (10 pairs of reads representing the minor resistant 
subpopulation) (Colman et al., 2015). 
The benefit of next generation targeted deep sequencing is that it is potentially a much faster 
diagnostic assay, once the workflow has been established, compared to culture diagnostic method 
that requires a minimum of 4 to 6 weeks (Tolani et al., 2012). Furthermore, next generation 
targeted deep sequencing provides a resistance profile as well as quantitative analysis of variants 
present within M. tuberculosis populations. The ratio of resistant to susceptible alleles allows for 
intensive examination of the emergence of low-level genetic resistance during the course of 
treatment. The Illumina platform was also found to be cost effective and more reliable to use than 
the Ion torrent platform for targeted deep sequencing as it has a lower error rate (e.g. 0.2% 
compared to Ion torrent (e.g. 0.5%) which needs to be considered especially when one wants to 
detect low frequency underlying variants with confidence. 
Several limitations were identified in this study. Firstly, not all the mutations conferring FQ 
resistance are known. Secondly, different mutations confers resistance to a single anti-TB drug 
(e.g. FQs), necessitating sequencing of more than one genomic region. Thirdly, rare variants can 
become lost or altered during the DNA extraction procedure, sample transport, sample 
decontamination procedure or may be altered during culturing. Fourthly, the detection of 
heteroresistance also depends on the sensitivity of the molecular technique used in a study, since 
the current molecular techniques have variable detection limits for detection of low frequency 
underlying genomic mutations conferring drug resistance. Furthermore, NGS-based diagnostic 
methods are also costly, resource dependant and labour intensive and require highly advanced 




technology and expertise. Lastly, targeted deep sequencing platforms possess intrinsic sequencing 
error rates, possibly obscuring true variants. 
In future studies, we want to expand the study using a larger sample set and investigate more drug 
resistance conferring genes, which will provide us with more comprehensive information on the 
prevalence of heteroresistance. Competition assays using different FQ resistant mutants at 
different ratios can be done in vitro to determine the fitness cost in relation to the initial inoculum of 
both mutant isolates. Furthermore, the growth rate of minority variants can be determined by 
studying the growth of underlying variants on different growth media, as different growth media 
result in variation in growth rates which would affect phenotypic resistance tests (Rinder et al., 
2001). Alternatively, multiple FQ susceptible isolates can be sequenced to determine the 
sequencing error rate at each position of the target to increase our ability to distinguish between 
low frequency variants (<0.2%) and sequencing error. 
In summary, next generation targeted deep sequencing is a potential emerging diagnostic method 
that allows for sample and target multiplexing. Thus, allowing for simultaneous detection and 
characterisation of numerous genetic targets within a short time frame (approximately 4 weeks, 
when considering all the steps from DNA isolation, PCR amplification, library preparation, deep 
sequencing and data analysis), compared to culture (i.e. 6 to 8 weeks). Furthermore, next 
generation targeted deep sequencing which involves amplicon sequencing can be applied to low 
levels of DNA concentration (e.g. serial dilution) and is able to detect very low frequencies of 
genetic variant subpopulations at very high coverage (Colman et al., 2015).  




Chapter 6: Conclusion 
Targeted deep sequencing was used to detect underlying variants within the M. tuberculosis 
fluoroquinolone resistance causing genes (gyrA and gyrB). Using synthethic heterogeneous 
mixtures we were able to establish a targeted deep sequencing method that could accurately 
detect the correct proportion of mutant DNA. The Illumina MiSeq platform were shown to be 
superior to the Ion Torrent PGM platform as it accurately reflected the known proportion of mutant 
DNA to a minimum frequency of 0.1% when using the analysis pipeline as described by Colman et 
al. (2015) (Colman et al., 2015). We also found that a minimum coverage of 6250 time is adequate 
to detect low frequency underlying variant, which were in agreement with previous findings 
(Colman et al., 2015). From this study we have seen that NGS targeted deep sequencing can 
confidently diagnose underlying variants present at very low frequencies in patient samples that 
were deemed FQ sensitive by standard DST. These minority variants were consequently found to 
be fixed in the follow up patient isolates, suggesting the evolution and the subsequent selection of 
the FQ resistant population during the course of treatment. Having this knowledge may guide 
prescription of adequate treatment to patients and prevent the amplification of drug resistance. In 
contrast FQ susceptible (as determined by standard DST) patient isolates from a clinical trial 
showed constant low frequency variants (<0.1%) in the baseline as well as follow up isolates. This 
could possibly be due to the predicted error rate of the Illumina MiSeq sequencing platform or 
effect of combination treatment that effectively suppresses the minority FQ resistant population. 
This method also allowed for the identification of variants in gyrA with fluctuating frequencies 
during the evolution of FQ resistance, indicating the dynamic mechanisms for the development of 
FQ resistance. In summary the aims of this study were successfully achieved as an ultra-sensitive 
method to detect underlying resistance causing mutations using a targeted deep sequencing 
approach was developed. 







Primer sequences were tested to find optimal primer sets for both, the QRDR of gyrA and - gyrB genes. Two primer sets were used in this 
study (methods Table 2).  
Table A 1 Primer (Oligonucleotide) sequences of the QRDR of gyrA and - gyrB genes. 









Forward ccggtcggttgccgagacc 19 70.6 73.7 
107 (Chakravorty et al., 2011) 
gyrA_Option1_R Reverse ccagcgggtagcgcagcgaccag 23 61.8 60.0 
gyrA_Option2_F 
gyrA 
Forward ggtgctctatgcaatgttcg 20 59.3 50.0 
236  
gyrA_Option2_R Reverse gggcttcggtgtacctcat 19 59.9 57.9 
gyrA_Colman_F 
gyrA 
Forward gggtgctctatgcaatgttcgat 23 64.5 47.8 
237 (Colman et al., 2015) 
gyrA_Colman_R Reverse gggcttcggtgtacctcatc 20 61.8 60.0 
gyrA_Option3_F 
gyrA 
Forward ggtgctctatgcaatgttcg 20 59.3 50.0 
272  
gyrA_Option3_R Reverse tttccctcagcatctccatc 20 60.2 50.0 
gyrA_Option4_F 
gyrA 
Forward tgacatcgagcaggagatgc 20 62 55 
344  
gyrA_Option4_R Reverse gggcttcggtgtacctcatc 20 62 60 
gyrB_Option1_F 
gyrB 
Forward accgacatcggtggattg 18 60.3 55.6 
284  
gyrB_Option1_R Reverse atcttgtggtagcgcagctt 20 60.0 50.0 
gyrB_Option2_F 
gyrB 
Forward cgtaaggcacgagagttggt 20 60.3 55.0 
320  
gyrB_Option2_R Reverse atcttgtggtagcgcagctt 20 60.0 50.0 
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Forward accgacatcggtggattg 18 60.3 55.6 
261  
gyrB_Option3_R Reverse gatatcgaactcgtcgtggat 21 59.0 47.6 
gyrB_Option4_F 
gyrB 
Forward aagagcgccaccgacatc 18 62.18 61.11 
300  
gyrB_Option4_R Reverse cagcacgatcttgtggtagc 20 62.45 55 
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Additional optimisation of different combinations of the forward and reverse primer sequences for the QRDR region of gyrB were tested, 
to determine the most specific and sensitive primer set (Appendix Table A 2). 
Table A 2 Different combinations of the forward and reverse primer sequences for the QRDR region of gyrB. 
Name of primer set Lable Position Primer sequence Average 
Tm (⁰ C) 
Start product size 
1 gyrB_Option1_F Forward accgacatcggtggattg 59,9 1414 291 
gyrB_Option4_R Reverse cagcacgatcttgtggtagc 1704 
2 gyrB_Option1_F Forward accgacatcggtggattg 59,65 1414 261 
gyrB_Option3_R Reverse gatatcgaactcgtcgtggat 1674 
3 gyrB_Option2_F Forward cgtaaggcacgagagttggt 59,9 1378 327 
gyrB_Option4_R Reverse cagcacgatcttgtggtagc 1704 
4 gyrB_Option2_F Forward cgtaaggcacgagagttggt 59.65 1378 299 
gyrB_Option3_R Reverse gatatcgaactcgtcgtggat 1674 
5 gyrB_Option4_F Forward aagagcgccaccgacatc 60,95 1405 300 
gyrB_Option4_R Reverse cagcacgatcttgtggtagc 1704 
6 gyrB_Option4_F Forward aagagcgccaccgacatc 61.09 1405 295 
gyrB_Option1_R Reverse atcttgtggtagcgcagctt 1697 
7 gyrB_Option4_F Forward aagagcgccaccgacatc 60,7 1405 270 
gyrB_Option3_R Reverse gatatcgaactcgtcgtggat 1674 
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PCR primers (Table 1 and Table 2) were first optimized in monoplex PCR reactions. A PCR 
protocol adapted from Colman et al., 2015 (Table 4) were used in the combination of 
different PCR parameters (Table 3). This included testing different magnesium chloride 
concentrations as well in the presence or absence of Betaine and DMSO. Different PCR 
conditions including different melting temperatures, cycle numbers and elongation times 
were also tested (Table 3). The following parameters were selected finally after several 
trials to find the most optimum method to amplify the regions of interest (Table 5).  
Table A 3 Parameters tested to obtain an optimal PCR reaction. 
 Parameters 
Melting temperature (°C) 55 – 65 
Magnesium chloride (MgCl2) 1.5 mM, 2 mM, 3 mM 
Betaine solution With and without 
Dimethyl sulfoxide (DMSO) With and without 
Number of cycles 25 – 45 
Elongation time (sec) 10 - 40 
 








Q5 High-Fidelity 2X Master Mix with Betaine solution 
Components 25 µl Reaction 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5 µl 
10 µM Forward Primer 1.25 µl 
10 µM Reverse Primer 1.25 µl 
5 M Betaine solution (Sigma-Aldrich) 5 µl 
Template DNA 2 µl 
Nuclease-Free Water to 25 µl 





























Q5 High-Fidelity 2X Master Mix without Betaine solution 
Components 25 µl Reaction 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5 µl 
10 µM Forward Primer 0.05 µl 
10 µM Reverse Primer 0.05 µl 
Template DNA 1 µl 
Nuclease-Free Water 11.4 (to 25 µl) 
Thermo-cycling conditions for PCR 
Initial denaturation 98°C for 1 min 
Denaturation 98°C for 10 sec 
Annealing 60°C for 15 sec 
Extension 72°C for 2 min 
Number of cycles 35 
Thermo-cycling conditions for PCR 
Initial denaturation 98°C for 1 min 
Denaturation 98°C for 10 sec 
Annealing 62°C for 15 sec 
Extension 72°C for 2 min 
Number of cycles 45 





In vitro mixtures 
The isolated DNA for both H37Rv and BO1 was pre-heated at 65 °C for 10 minutes. DNA 
concentrations were determined using the NanoDrop spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). A DNA concentration of 2051.033 ng/ul was determined for the 
H37Rv while, a DNA concentration of 1529.567 ug/ml was determined for BO1. Due to the high 
concentration of the H37Rv DNA, the DNA was firstly diluted to a lower concentration (683.677 
ug/ml) by mixing 600ul of H37Rv DNA with 1200 ul TE buffer. The actual concentration of this 
mixture was then confirmed with the NanoDrop spectrophotometer to be 701.3 ng/ul. For BO1, a 
2:1 dilution in TE buffer was first made, resulting in a concentration as determined by the Nanodrop 
of 774 ng/ul. Subsequently, this concentration was further diluted to a final concentration of 200 
ug/ml. A dilution series ranging from 100% (5 ul mutant DNA in the background of 0 ul wildtype 
DNA) and 0% (0 ul mutant DNA in the background of 5 ul wildtype DNA) was then made using the 
diluted DNA samples of H37Rv and BO1. Certain pre-calculated volumes, dependent on the DNA 
concentration, of each DNA sample was used to create the different mutant to wild type ratios. For 
this purpose a constant volume of BO1 DNA was added to different volume of H37Rv DNA. A 
nanodrop reading was taken of each mixture and diluted to 25 ug/ml needed for the PCR 
reactions. 
  














Al-Mutairi, N.M., Ahmad, S. & Mokaddas, E. 2011. First report of molecular detection of 
fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium 
tuberculosis isolates in Kuwait. BMC research notes. 4:123. 
Behr, M.A. 2004. Tuberculosis due to multiple strains: a concern for tuberculosis control? American 
Journal of Respiratory and Critical Care Medicine. 169(5):553–554. 
Black, P.A., Vos, M. De, Louw, G.E., Merwe, R.G. Van Der, Dippenaar, A., Streicher, E.M., 
Abdallah, A.M. & Sampson, S.L. 2015. Whole genome sequencing reveals genomic heterogeneity 
and antibiotic purification in Mycobacterium tuberculosis isolates. BMC Genomics. 1–14. 
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M.R., Chakravorty, S., Jones, M., 
et al. 2010. Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay. Journal of 
Clinical Microbiology. 48(7):2495–2501. 
Boehme, C.C., Nicol, M.P., Nabeta, P., Michael, J.S., Gotuzzo, E., Tahirli, R., Gler, M.T., 
Blakemore, R., et al. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use 
of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre 
implementation study. The Lancet. 377(9776):1495–1505. 
Bryant, J.M., Harris, S.R., Parkhill, J., Dawson, R., Diacon, A.H., van Helden, P., Pym, A., 
Mahayiddin, A.A., et al. 2013. Whole-genome sequencing to establish relapse or re-infection with 
Mycobacterium tuberculosis: a retrospective observational study. The lancet.Respiratory medicine. 
1(10):786–792. 
Campbell, P.J., Morlock, G.P., Sikes, R.D., Dalton, T.L., Metchock, B., Starks, A.M., Hooks, D.P., 
Cowan, L.S., et al. 2011. Molecular Detection of Mutations Associated with First- and Second-Line 
Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium 
tuberculosis. Antimicrobial Agents and Chemotherapy. 55(5):2032–2041. 
Cegielski, J.P., Dalton, T., Yagui, M., Wattanaamornkiet, W., Volchenkov, G. V., Via, L.E., Van Der 
Walt, M., Tupasi, T., et al. 2014. Extensive Drug Resistance Acquired During Treatment of 
Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases. 59(8):1049–1063. 
Chakravorty, S., Aladegbami, B., Thoms, K., Lee, J.S., Lee, E.G., Rajan, V., Cho, E.J., Kim, H., et 
al. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium 
tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-
time PCR assay. Journal of Clinical Microbiology. 49(3):932–940. 
Chatterjee, M., Bhattacharya, S., Karak, K. & Dastidar, S.G. 2013. Effects of different methods of 
decontamination for successful cultivation of Mycobacterium tuberculosis. Indian Journal of 
Medical Research. 138(OCT):541–548. 




Cock, P.J., Fields, C.J., Goto, N., Heuer, M.L. & Rice, P.M. 2010. The Sanger FASTQ file format 
for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic acids 
research. 38(6):1767–1771. 
Cohen, T., Chindelevitch, L., Misra, R., Kempner, M.E., Galea, J., Moodley, P. & Wilson, D. 2016. 
Within-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early 
Treatment Response A Prospective Cohort Study. The Journal of infectious diseases. 213:2005–
2011. 
Coll, F., McNerney, R., Preston, M.D., Guerra-Assunção, J.A., Warry, A., Hill-Cawthorne, G., 
Mallard, K., Nair, M., et al. 2015. Rapid determination of anti-tuberculosis drug resistance from 
whole-genome sequences. Genome medicine. 7(1):51. 
Colman, R.E., Schupp, J.M., Hicks, N.D., Smith, D.E., Buchhagen, L., Valafar, F., Crudu, V. & 
Romancenco, E. 2015. Detection of Low-Level Mixed-Population Drug Resistance in 
Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing. 1–18. 
Colman, R.E., Anderson, J., Lemmer, D., Lehmkuhl, E., Georghiou, S.B., Heaton, H., Wiggins, K., 
Gillece, J.D., et al. 2016. Rapid Drug Susceptibility Testing of Drug Resistant Mycobacterium 
tuberculosis Directly from Clinical Samples using Amplicon Sequencing: A Proof of Concept Study. 
Journal of Clinical Microbiology. (May):JCM.00535–16. 
Consortium, W.W.W. 1999. HTML 4.01 specification. 
DePristo, M.A., Banks, E., Poplin, R.E., Garimella, K. V, Maguire, J.R., Hartl, C., Rivas, M.A., 
Hanna, M., et al. 2011. A framework for variation discovery and genotyping using nextgeneration 
DNA sequencing data. 43(5):491–498. 
Eilertson, B., Maruri, F., Blackman, A., Herrera, M., Samuels, D.C. & Sterling, T.R. 2014. High 
proportion of heteroresistance in gyra and gyrb in fluoroquinolone-resistant mycobacterium 
tuberculosis clinical isolates. Antimicrobial Agents and Chemotherapy. 58(6):3270–3275. 
Eldholm, V., Norheim, G., von der Lippe, B., Kinander, W., Dahle, U.R., Caugant, D. a, Mannsåker, 
T., Mengshoel, A.T., et al. 2014. Evolution of extensively drug-resistant Mycobacterium 
tuberculosis from a susceptible ancestor in a single patient. Genome Biology. 15(11):490. 
El-Halfawy, O.M. & Valvano, M.A. 2015. Antimicrobial heteroresistance: An emerging field in need 
of clarity. Clinical Microbiology Reviews. 28(1):191–207. 
Engström, A., Hoffner, S. & Juréen, P. 2013. Detection of heteroresistant Mycobacterium 
tuberculosis by pyrosequencing. Journal of Clinical Microbiology. 51(12):4210–4212. 
Farhat, M.R., Shapiro, B.J., Kieser, K.J., Sultana, R., Jacobson, K.R., Victor, T.C., Warren, R.M., 
Streicher, E.M., et al. 2013. Genomic analysis identifies targets of convergent positive selection in 




drug-resistant Mycobacterium tuberculosis. Nature genetics. 45(10):1183–1189. 
Folkvardsen, D.B., Thomsen, V.O., Rigouts, L., Rasmussen, E.M., Bang, D., Bernaerts, G., 
Werngren, J., Toro, J.C., et al. 2013. Rifampin heteroresistance in Mycobacterium tuberculosis 
Cultures as Detected by phenotypic and genotypic drug susceptibility test methods. Journal of 
Clinical Microbiology. 51(12):4220–4222. 
Folkvardsen, D.B., Svensson, E., Thomsen, V., Rasmussen, E.M., Bang, D., Werngren, J., 
Hoffner, S., Hillemann, D., et al. 2013. Can molecular methods detect 1% isoniazid resistance in 
mycobacterium tuberculosis? Journal of Clinical Microbiology. 51(5):1596–1599. 
Gardy, J.L., Johnston, J.C., Ho Sui, S.J., Cook, V.J., Shah, L., Brodkin, E., Rempel, S., Moore, R., 
et al. 2011. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. 
The New England journal of medicine. 364(8):730–739. 
Hofmann-Thiel, S., Van Ingen, J., Feldmann, K., Turaev, L., Uzakova, G.T., Murmusaeva, G., Van 
Soolingen, D. & Hoffmann, H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of 
Mycobacterium tuberculosis in Tashkent, Uzbekistan. European Respiratory Journal. 33(2):368–
374. 
Hughes, J., Cardiff, M.B.B., Osman, M., Chb, M.B., Dip, P.G. & Management, H. 2014. Diagnosis 
and management of drug-resistant tuberculosis in South African adults. 104(12). 
Illumina. 2016. [Online], Available: http://www.illumina.com/technology/next-generation-
sequencing/deep-sequencing.html [2016, January 15]. 
Ioerger, T.R., O’Malley, T., Liao, R., Guinn, K.M., Hickey, M.J., Mohaideen, N., Murphy, K.C., 
Boshoff, H.I., et al. 2013. Identification of new drug targets and resistance mechanisms in 
Mycobacterium tuberculosis. PloS one. 8(9):e75245. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., et al. 
2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics (Oxford, England). 
25(16):2078–2079. 
Marlowe, E.M., Novak-Weekley, S.M., Cumpio, J., Sharp, S.E., Momeny, M.A., Babst, A., Carlson, 
J.S., Kawamura, M., et al. 2011. Evaluation of the cepheid xpert MTB/RIF assay for direct 
detection of mycobacterium tuberculosis complex in respiratory specimens. Journal of Clinical 
Microbiology. 49(4):1621–1623. 
Mayer, C. & Takiff, H. 2014. The Molecular Genetics of Fluoroquinolone Resistance in 
Mycobacterium tuberculosis. Microbiology Spectrum. 2(4):1–22. 
McElroy, K., Thomas, T. & Luciani, F. 2014. Deep sequencing of evolving pathogen populations: 
applications, errors, and bioinformatic solutions. Microbial informatics and experimentation. 4(1):1. 




McGrath, M; Warren, RM; van Pittius, CG; Sampson, S. 2016. Evolution of XDR-TB and the 
associated proteome. Stellenbosch University. 
Meacci, F., Orrù, G., Iona, E., Piersimoni, C., Pozzi, G., Oggioni, M.R., Orru, G. & Giannoni, F. 
2005. Drug Resistance Evolution of a Mycobacterium tuberculosis Strain from a Noncompliant 
Patient Drug Resistance Evolution of a Mycobacterium tuberculosis Strain from a Noncompliant 
Patient. 43(7):3114–3120. 
Mekonnen, D., Admassu, A., Mulu, W., Amor, A., Benito, A., Gelaye, W., Biadglegne, F. & Abera, 
B. 2015. Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene 
mutations in Ethiopia. International Journal of Infectious Diseases. 39:34–38. 
Merker, M., Kohl, T.A., Roetzer, A., Truebe, L., Richter, E., Rusch-Gerdes, S., Fattorini, L., 
Oggioni, M.R., et al. 2013. Whole genome sequencing reveals complex evolution patterns of 
multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PloS one. 8(12):e82551. 
Miotto P.; Cirillo D.M.; Migliori B; 2015. Drug Resistance in Mycobacterium tuberculosis. 
Antimicrobial Resistance in Developing Countries. 117. 
NCBI. 1997. Standard Nucleotide BLAST. [Online], Available: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch [2015, May 26]. 
New England Biolabs Inc. n.d. Q5® Hot Start High-Fidelity 2X Master Mix. [Online], Available: 
https://www.neb.com/products/m0494-q5-hot-start-high-fidelity-2x-master-mix [2004, May 20]. 
Pantel, A., Petrella, S., Veziris, N., Brossier, F., Bastian, S., Jarlier, V., Mayer, C. & Aubry, A. 2012. 
Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium 
tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrobial 
Agents and Chemotherapy. 56(4):1990–1996. 
Pholwat, S., Stroup, S., Foongladda, S. & Houpt, E. 2013. Digital PCR to detect and quantify 
heteroresistance in drug resistant Mycobacterium tuberculosis. PloS one. 8(2):e57238. 
Quail, M.A., Smith, M.E., Coupland, P., Otto, T.D., Harris, S.R., Connor, T.R., Bertoni, A., 
Swerdlow, H.P., et al. 2012. A tale of three next generation sequencing platforms: comparison of 
Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC genomics. 13(1):341. 
Rahman, A., Sahrin, M., Afrin, S., Earley, K. & Ahmed, S. 2016. Comparison of Xpert MTB / RIF 
Assay and GenoType MTBDR plus DNA Probes for Detection of Mutations Associated with 
Rifampicin Resistance in Mycobacterium tuberculosis. 1–11. 
Rhoads, A. & Au, K.F. 2015. PacBio Sequencing and Its Applications. Genomics, Proteomics and 
Bioinformatics. 13(5):278–289. 
van Rie, A., Victor, T.C., Richardson, M., Johnson, R., van der Spuy, G.D., Murray, E.J., Beyers, 




N., van Pittius, N.C.G., et al. 2005. Reinfection and Mixed Infection Cause Changing 
Mycobacterium tuberculosis Drug-Resistance Patterns. American Journal of Respiratory and 
Critical Care Medicine. 172(5):636–642. 
van Rie, A., Mellet, K., John, M., Scott, L., Dansey, H. & Victor, T. 2013. False-positive rifampicin 
resistance on Xpert ® MTB / RIF : case report and clinical implications. Int J Tuberc Lung Dis. 
16(2):206–208. 
Rinder, H. 2001. Hetero-resistance: An under-recognised confounder in diagnosis and therapy? 
Journal of Medical Microbiology. 50(12):1018–1020. 
Rinder, H., Mieskes, K.T. & Löscher, T. 2001. Heteroresistance in Mycobacterium tuberculosis. 
International Journal of Tuberculosis and Lung Disease. 5(4):339–345. 
Roetzer, A., Diel, R., Kohl, T.A., Ruckert, C., Nubel, U., Blom, J., Wirth, T., Jaenicke, S., et al. 
2013. Whole genome sequencing versus traditional genotyping for investigation of a 
Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS 
medicine. 10(2):e1001387. 
Schurch, A.C., Kremer, K., Daviena, O., Kiers, A., Boeree, M.J., Siezen, R.J. & van Soolingen, D. 
2010. High-resolution typing by integration of genome sequencing data in a large tuberculosis 
cluster. Journal of clinical microbiology. 48(9):3403–3406. 
Schurch, A.C., Kremer, K., Kiers, A., Daviena, O., Boeree, M.J., Siezen, R.J., Smith, N.H. & van 
Soolingen, D. 2010. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at 
patient-to-patient scale. Infection, genetics and evolution : journal of molecular epidemiology and 
evolutionary genetics in infectious diseases. 10(1):108–114. 
Streicher, E.M., Bergval, I., Dheda, K., Bottger, E.C., Gey van Pittius, N.C., Bosman, M., Coetzee, 
G., Anthony, R.M., et al. 2012. Mycobacterium tuberculosis population structure determines the 
outcome of genetics-based second-line drug resistance testing. Antimicrobial Agents and 
Chemotherapy. 56(5):2420–2427. 
Streicher, E.M., Muller, B., Chihota, V., Mlambo, C., Tait, M., Pillay, M., Trollip, A., Hoek, K.G., et 
al. 2012. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant 
(XDR) tuberculosis in South Africa. Infection, genetics and evolution : journal of molecular 
epidemiology and evolutionary genetics in infectious diseases. 12(4):686–694. 
Sun, G., Luo, T., Yang, C., Dong, X., Li, J., Zhu, Y., Zheng, H., Tian, W., et al. 2012. Dynamic 
population changes in Mycobacterium tuberculosis during acquisition and fixation of drug 
resistance in patients. The Journal of infectious diseases. 206(11):1724–1733. 
ThermoFisherScientific. 2013. Torrent Suite Software 4.0 User Guide. [Online], Available: 
https://ioncommunity.thermofisher.com/docs/DOC-9589 [2016, February 12]. 




Theron, G., Peter, J., Van Zyl-Smit, R., Mishra, H., Streicher, E., Murray, S., Dawson, R., 
Whitelaw, A., et al. 2011. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary 
tuberculosis in a high HIV prevalence setting. American Journal of Respiratory and Critical Care 
Medicine. 184(1):132–140. 
Tolani, M.P., D’Souza D, T. & Mistry, N.F. 2012. Drug resistance mutations and heteroresistance 
detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in 
patients from Mumbai, India. BMC Infect Dis. 12(1):9. 
Untergasser, A., Nijveen, H., Rao, X., Bisseling, T., Geurts, R. & Leunissen, J.A. 2007. 
Primer3Plus, an enhanced web interface to Primer3. Nucleic acids research. 35(Web Server 
issue):W71–4. 
Walker, T.M., Ip, C.L., Harrell, R.H., Evans, J.T., Kapatai, G., Dedicoat, M.J., Eyre, D.W., Wilson, 
D.J., et al. 2013. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a 
retrospective observational study. The Lancet infectious diseases. 13(2):137–146. 
Wang, J.Y., Lee, L.N., Lai, H.C., Wang, S.K., Jan, I.S., Yu, C.J., Hsueh, P.R. & Yang, P.C. 2007. 
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations 
and relationship to antimicrobial exposure. The Journal of antimicrobial chemotherapy. 59(5):860–
865. 
Wang, X., Liu, H., Wei, J., Wu, X., Yu, Q., Zhao, X., Lyu, J., Lou, Y., et al. 2015. An investigation 
on the population structure of mixed infections of Mycobacterium tuberculosis in Inner Mongolia, 
China. Tuberculosis (Edinburgh, Scotland). 95(6):695–700. 
Warren, R., Kock, M. De, Engelke, E., Myburgh, R., Pittius, N.G. Van, Victor, T. & Helden, P. Van. 
2006. Safe Mycobacterium tuberculosis DNA Extraction Method That Does Not Compromise 
Integrity. 44(1):254–256. 
Warren, R.M., Victor, T.C., Streicher, E.M., Richardson, M., Beyers, N., Gey van Pittius, N.C. & 
van Helden, P.D. 2004. Patients with active tuberculosis often have different strains in the same 
sputum specimen. American journal of respiratory and critical care medicine. 169(5):610–614. 
Wedajo, W., Schön, T., Bedru, A., Kiros, T., Hailu, E., Mebrahtu, T., Yamuah, L., Ängeby, K., et al. 
2014. A 24-well plate assay for simultaneous testing of first and second line drugs against 
Mycobacterium tuberculosis in a high endemic setting. BMC research notes. 7:512. 
WHO. 2008a. Policy guidance on drug-susceptibility testing ( DST ) of second-line antituberculosis 
drugs World Health Organization. World Health. 1–20. 
WHO. 2008b. Molecular line probe assays for rapid screening of patients at risk of multidrug-
resistant tuberculosis (MDR-TB). Policy statement. (June):1–9. [Online], Available: 
http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:MOLECULAR+LINE+PROBE+AS






WHO. 2011. AUTOMATED REAL-TIME NUCLEIC ACID AMPLIFICATION TECHNOLOGY FOR 
RAPID AND SIMULTANEOUS DETECTION OF TUBERCULOSIS AND RIFAMPICIN 
RESISTANCE : Xpert MTB / RIF SYSTEM POLICY STATEMENT. World Health. 1–35. 
WHO. 201 . Xpert MTB/RIF implementation manual Technical and operational “how-to”: practical 
considerations. WHO Manual. 
WHO. 2015a. Global tuberculosis report 2015. Igarss 2014. (1):1–5. 
WHO. 2015b. Tuberculosis mortality nearly halved since 1990. WHO. [Online], Available: 
http://www.who.int/mediacentre/news/releases/2015/tuberculosis-mortality/en/. 
World Health Organization. 2007. TB diagnostics and laboratory strengthening - WHO policy. 
Definition of a new sputum smear-positive TB case, 2007. Geneva, Switzerland: WHO, 2007. 
[Online], Available: http://www.who.int/tb/laboratory/policy_sputum_smearpositive_tb_case/en/ 
[2015, November 11]. 
World Health Organization. 2016. Tuberculosis. [Online], Available: 
http://www.who.int/mediacentre/factsheets/fs104/en/ [2016, April 13]. 
Zetola, N.M., Shin, S.S., Tumedi, K.A., Moeti, K., Ncube, R., Nicol, M., Collman, R.G., Klausner, 
J.D., et al. 2014. Mixed Mycobacterium tuberculosis complex infections and false-negative results 
for rifampin resistance by genexpert MTB/RIF are associated with poor clinical outcomes. Journal 
of Clinical Microbiology. 52(7):2422–2429. 
Zhang, X., Zhao, B., Liu, L., Zhu, Y., Zhao, Y. & Jin, Q. 2012. Subpopulation analysis of 
heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. 
Journal of clinical microbiology. 50(4):1471–4. 
Zhang, Z., Lu, J., Wang, Y., Pang, Y. & Zhao, Y. 2014. Automated liquid culture system misses 
isoniazid heteroresistance in Mycobacterium tuberculosis isolates with mutations in the promoter 
region of the inhA gene. European Journal of Clinical Microbiology & Infectious Diseases. 
34(3):555–560. 
Zhang, Z., Wang, Y., Pang, Y. & Liu, C. 2014. Comparison of different drug susceptibility test 
methods to detect the rifampin heteroresistance in Mycobacterium tuberculosis. Antimicrobial 
agents and chemotherapy. 58(155):5632–5635. 
 
Stellenbosch University  https://scholar.sun.ac.za
